





Implementation of machine learning in evidence syntheses in the Cluster for Reviews and Health Technology Assessments: Final report 2020-2021

Utgitt av	Folkehelseinstituttet		
	Område for helsetjenester		
Tittel	Implementering av maskinlæring i kunnskapsoppsummeringer i klynge		
	for vurdering av tiltak: Sluttrapport 2020-2021		
English title	Implementation of machine learning in evidence syntheses in the Clus-		
	ter for Reviews and Health Technology Assessments: Final report 2020-		
	2021		
Ansvarlig	Camilla Stoltenberg, direktør		
Forfattere	Ashley Elizabeth Muller, prosjektleder, Folkehelseinstituttet		
	Heather Ames, Folkehelseinstituttet		
	Jan Himmels, Folkehelseinstituttet		
	Patricia Jacobsen Jardim, Folkehelseinstituttet		
	Lien Nguyen, Folkehelseinstituttet		
	Christopher Rose, Folkehelseinstituttet		
	Stijn van de Velde, Folkehelseinstituttet		
ISBN	978-82-8406-231-0		
Publikasjonstype	Report (Rapport)		
Antall sider	29 (79 inklusiv vedlegg)		
Oppdragsgiver	Folkehelseinstituttet		
Emneord(MeSH)	biomedical; technological assessment, health; unsupervised machine		
	learning; supervised machine learning; deep learning		
Sitering	Muller AE, Ames H, Himmels J, Jardim PJ, Nguyen L, Rose C, Van de Velde		
	S. Implementering av maskinlæring i kunnskapsoppsummeringer i		
	klynge for vurdering av tiltak: Sluttrapport 2020-2021 [Implementation		
	of machine learning in evidence syntheses in the Cluster for Reviews		
	and Health Technology Assessments: Final report 2020-2021] –2021.		
	Oslo: Folkehelseinstituttet, 2021.		

# **Table of contents**

TABLE OF CONTENTS	2
KEY MESSAGES	3
HOVEDBUDSKAP	4
PREFACE	5
BACKGROUND	6
PROJECT RESULTS	7
Time and resources	7
Internal team capacity building and team-building	7
Implementation and training	7
Testing and validation	9
Priority screening	11
Classifiers	12
RobotReviewer to assess Risk of Bias	16
Automatic text clustering	18
Microsoft Academic Graph (MAG)	20
Collaboration outside of the ML team	22
National Institute for Health Care Excellence and EPPI Centre	22
University of North Carolina	22
NIPH 22	
Dissemination outputs	22
User-friendly summaries of machine learning functions	22
User guides adapted to NIPH workflows	23
Manuscripts	23
Presentations	23
Strategy-related outputs	24
LESSONS LEARNED	27
APPENDICES	29

## **Key Messages**

Machine learning (ML) has the potential to increase the efficiency of evidence syntheses. During 2020-2021, a team in the division for Health Services at the Norwegian Institute of Public Health, tested and documented pros and cons of using ML in various phases of the conduct of various evidence syntheses, and built employees' competence in using ML. This report describes the work undertaken by the ML team, project results and lessons learned.

The ML team focused attention on ML functions and systems available within EPPI Reviewer: Priority screening, Custom and Pre-built classifiers, RobotReviewer to assess Risk of Bias, Automatic text clustering, and Microsoft Academic Graph (MAG). We implemented ML functions across 19 project teams and trained 23 employees. We found that utilizing ML in our reviews increased speed, with no identified threats to methodological quality. Screening time was reduced by 60-90% in all projects. Automated study categorization – while applicable to a smaller range of projects – reduced manual time in this phase by 60-70%.

ML can, and should, change usual project workflows. The review process can become less linear and more cyclical, and several tasks can be conducted in parallel. However, workflow changes are not insignificant for those involved, and future ML work would benefit from a structured approach to both change management and innovation diffusion.

The report concludes with lessons learned and experiences gained. They shaped our proposals for future ML strategies, covering capacity-building, innovative activities, evaluation of effect, and workflow optimization.

#### Title:

Implementation of machine learning in evidence syntheses in the Cluster for Reviews and Health Technology Assessments: Final report 2020-2021

#### Publisher:

The Norwegian Institute of Public Health conducted the project based on an initiative by the Cluster of Reviews and Health Technology Assessments, Division for Health Services at the NIPH

Type of publication: Report

Activity timeline: Dec 2020 - June 2021

## Machine learning functions evaluated and implemented:

Priority screening Classifiers (3 types) RobotReviewer to assess Risk of Bias Automatic text clustering Microsoft Academic Graph (MAG)

## Hovedbudskap

Maskinlæring kan bidra til betydelig effektivisering av kunnskapsoppsummeringsprosesser. Et lag i Området for helsetjenester ved Folkehelseinstituttet evaluerte og dokumenterte i 2020-2021 fordeler og ulemper ved maskinlæring i flere faser av kunnskapsoppsummeringer, og bygde medarbeidernes kompetanse i å bruke ulike funksjoner. Denne rapporten beskriver lagets arbeid, resultater og erfaringer.

Maskinlæringslaget fokuserte på funksjoner som er tilgjengelig i EPPI-Reviewer verktøyet: «priority screening», flere typer classifiers, RobotReviewer for å vurdere risiko av skjevheter, «automatic text clustering», og Microsoft Academic Graph. Vi implementerte funksjonene i 19 prosjekter og opplærte 23 medarbeidere. Et hovedfunn er at maskinlæringsfunksjoner reduserte manuell tidsbruk, uten reduksjon i metodisk kvalitet. Tidsbruk på vurdering av studier gikk ned med 60-90 % i alle prosjekter. Automatisk studiekategorisering reduserte tidsbruk i denne fasen med 60-70 %.

Maskinlæring kan og bør endre dagens arbeidsflyt. Kunnskapsoppsummeringsprosessen kan bli mindre lineær og mer syklisk, og flere oppgaver kan gjøres samtidig. Slike endringer kan være vesentlige for alle involverte, og i framtidig maskinlæringsarbeid vil det være nyttig med en strukturert tilnærming til både endringsledelse og innovasjonsspredning.

Rapporten avslutter med erfaringer og lærdommer. Disse formet vårt forslag til framtidige strategier relatert til kompetansebygging, innovasjonsaktiviteter, evalueringer og arbeidsflytoptimalisering.

#### Tittel:

Implementering av maskinlæring i kunnskapsoppsummeringer i klynge for vurdering av tiltak: Sluttrapport 2020-2021

#### Hvem står bak denne publikasjonen?

Folkehelseinstituttet utførte studien basert på et initiativ fra klynge for vurdering av tiltak, område for helsetjenster i FHI

**Type publikasjon:** Rapport

-----

**Tidsperiode for prosjektet:** Des 2020 - Juni 2021

Maskinlæringsfunksjoner som vi evaluerte og implementerte:

Priority screening Classifiers (3 types) RobotReviewer to assess Risk of Bias Automatic text clustering Microsoft Academic Graph (MAG)

## Preface

The Cluster for Reviews and Health Technology Assessments, Division for Health Services at the Norwegian Institute of Public Health (NIPH) decided in the fall of 2020 to conduct a project on machine learning related to the conduct of evidence syntheses. The goals were to test and document pros and cons of using machine learning in various phases of the conduct of evidence syntheses, as well as build employees' competence in using machine learning. A team of seven worked toward these goals from December 2020 until June 2021. This report describes their work.

The report is relevant for researchers and managers interested in implementing machine learning in their evidence syntheses. It is particularly relevant for evidence synthesis environments that do not have machine learning specialists.

#### Financing

The work was self-initiated and financed by the Cluster for Reviews and Health Technology Assessments, Division for Health Services at the NIPH.

#### **Team members**

Project leader: Ashley Elizabeth Muller Team members: Heather Ames, Jan Himmels, Patricia Jacobsen Jardim, Lien Nguyen, Christopher Rose, Stijn Van de Velde

#### **Conflicts of interest**

All authors declare they have no conflicts of interest.

Kåre Birger Hagen *Research director*  Rigmor C Berg Department director Ashley E. Muller Project leader

## Background

In early 2020, the Cluster for Reviews and Health Technology Assessments, Division for Health Services at the Norwegian Institute of Public Health (NIPH), became increasingly aware of the potential benefits of using machine learning (ML) in the conduct of evidence syntheses. Thus, the leader team in the cluster decided to initiate a project on ML. The project had two overarching goals: To test and document pros and cons of using ML in various phases of the conduct of evidence syntheses, and to build employees' competence in using ML. There were four objectives:

- Develop and implement a capacity-building ML strategy for the Cluster of Reviews and Health Technology Assessments
- Conduct a retrospective evaluation of ML performance in completed projects, and potentially evaluations in new projects, including recruiting and teaching project leaders
- Report results of capacity-building and evaluations to leadership and others in the Division for Health Services
- Stay abreast of methods and ongoing studies of ML in other health technology assessment organizations, and assess possibilities for collaboration

A team of seven employees (all but one) from the Cluster for Reviews and Health Technology Assessments, dedicated much of their time from December 2020 until June 2021 to the project.

The ML team's work was anchored in the preliminary NIPH strategies for the 2019-2024 period concerning automation, increasing speed of evidence syntheses, and work-flow and methods innovation. One of the goals of the division-specific strategies was for the Division for Health Services to become a leader in automation and digitalization of work processes, and to use these practices to summarize evidence more efficiently.

On a related note, we mention that during this report's preparation, the preliminary NIPH strategy was being revised. The machine learning team analyzed the preliminary strategic priorities and identified a need to integrate the ongoing, siloed ML activities at NIPH into a more cohesive, cross-division approach. Accordingly, the team began contacting, mapping and discussing with other actors and research teams in NIPH involved with ML. The strategy changes we proposed are included in the new NIPH strategy: "NIPH shall be a leader in big data, machine learning, and automation within public health", under strategic priority 7. We refer readers to a separate document which details our machine learning strategy.

## **Project results**

The following text details ML team activities undertaken January 2020 - May 2021.

### **Time and resources**

The team of seven, including two advisors, was allocated a maximum of twelve months' working time. The resources allocated to the team were adequate, although not fully exhausted by all team members. Some team members found it difficult to prioritize this team over projects with strict deliverables and timelines. The medium size of the team allowed us to work cooperatively and divide tasks among ourselves.

## Internal team capacity building and team-building

To bring team members unfamiliar with the field of ML up to date, and as a team-building exercise, we spent the first four weeks presenting new research and concepts to each other in weekly three-hour meetings, followed by discussions. Presentations are available for future use as a ML syllabus. We also used the first part of the year familiarizing ourselves with EPPI Reviewer and its functions.

## Implementation and training

The ML team supported the implementation of machine learning functions in 19 projects (including the original pilot project in August 2020). Twenty-three employees were trained, of which 18 were not members of the ML team. A list of projects and employees can be provided.

Table 1 gives an overview of the team's implementation and training activities.

Table 1: Overview of implementation and training activities

Machine learning function	Project teams	Employees <sup>a</sup> trained <sup>b</sup>	Training materials created
Priority screening	13	13	How-to guides in Norwegian and English, educational material
<u>Custom classifiers for</u> <u>screening</u>	10	6	How-to guide, educational material
<u>Pre-built study design</u> <u>classifiers</u>	1	2	Educational material
<u>Custom classifiers for</u> <u>study categorization</u>	1	3	Educational material
<u>RobotReviewer to as-</u> sess Risk of Bias	3	8	How-to guide for project leaders, how-to guide for project members, educational material
Automatic text cluste- ring	2	4	Educational material
<u>Microsoft Academic</u> <u>Graph (MAG)</u>	4	6	-
<sup>a</sup> Including ML team members. <sup>b</sup> Not all trained users can implement a function independently.			

To support project leaders with the implementation of new ML functions, we provided one-on-one training and technical assistance. Each project received a dedicated ML team member who trained the project leader first, and then the rest of the team, and was available for immediate assistance when needed. This intensive technical assistance ensured we were able to gather the data required for evaluation and validation activities, e.g. training time required. We used a training hand-off procedure to build capacity within the team: 1) a ML team trainee sat in on an experienced ML team member's training of a project; 2) both co-led the next training; 3) finally, the ML team trainee led a subsequent training, with the experienced member sitting in for assistance.

Intensive, often one-on-one technical assistance was necessary for project leaders to understand and implement particular functions, however, providing this level of intense assistance was not sustainable or scalable. In most cases, technical assistance was not sufficient for project leaders to become confident enough to train others, although it did build their confidence in choosing to use a particular technique in future projects.

Acknowledging that one-on-one technical assistance to all project leaders was not sustainable, we developed stand-alone training materials for project leaders and/or members. These materials encourage users to begin implementation independently of the ML team. At the time of report writing (June 2021), these materials are in the final phase of piloting and feedback collection. So far, the training materials have been successful in supporting project leaders to more independently implement ML functions, and reduce technical assistance needs from the machine learning team.

There remains uncertainty in responsibility for tasks among overlapping actors providing digital support: the digital tools team (and EPPI superuser within that team), the ML team, and EPPI software support. In response and in agreement with the digital tools team and leadership, responsibility was delegated for basic EPPI functions to the digital tools team and ML functions to the ML team. We also encouraged project leads to contact EPPI support for questions, but the threshold appeared higher for this than asking questions in-house. The new EPPI superuser's involvement in an early ML project has proven valuable as software skills were expanded with technical understanding of basic ML techniques – this overlap may be a prerequisite for optimal coordination between the two teams.

#### **Testing and validation**

While all ML functions available in EPPI-Reviewer are fully developed and have extensive documentation of validity, the majority lacked published validation studies specifically conducted within the field of evidence synthesis. We decided that internal/institutional evaluations of all functions were a necessary first step to increase trust and buyin among colleagues. Additionally, these evaluations provided a stronger foundation to evaluate particular functions' usefulness to our workflows. Almost all evaluations were integrated into ongoing projects, with exception of the retrospective evaluation of ML within screening (NICE is leading a simulation study of retrospective studies to identify "stopping criteria" for screening, while this team built and evaluated custom classifiers using previously completed projects) and a parallel initiative of our librarians to test Microsoft Academic Graph.

We created user-friendly introductions to each ML function; please see <u>User-friendly</u> <u>summaries of machine learning functions</u>. These 1-page, introductory infographics were developed to help project leaders understand the different functions, when to use them, and how to combine them.

In the following subsections we present how we tested and validated each of the functions as well as recommendations for next steps and/or implementation. Table 2 provides is a summary. Characteristics of each function is found in the description of each function further below.

Function	Relevant	Workflow	Benefits	Next steps
	review types	changes to		-
		optimize		
		benefits		
Priority screening	All	Single- or	60% less time used to	Scale up imple-
		auto-screen-	screen. Rapid team un-	mentation
			derstanding of inclu-	
		de-prioritiza-	sion criteria. Rapid	
		tion.	communication of po-	
			tential review size (or other issues) to com-	
			missioner.	
Custom classifiers	Reviews with	Single- or	60-90% less time used	Scale up imple-
for screening	clear inclusion	auto-screen-	to screen, when pre-	mentation
	criteria and re-		ceded by priority	
	search ques-	de-prioritiza-	screening	
	tions	tion.	0	
<u>Pre-built study de-</u>	Reviews of	Single- or	Accurately identify pri-	Scale up imple-
sign classifiers	RCTs. Over-	auto-screen-	oritized designs to re-	mentation
	views of SRs.		duce screening burden	
		de-prioritiza-		
	<b>D</b>	tion.		
<u>Custom classifiers</u> for study categoriza-	Review up-	Single- or	32-77% less time used	Evaluate further.
tion	dates. Rolling reviews. Litera-	auto-catego-	to categorize. Equally	Evoloro addi
	ture searches	rization (data extraction)	as accurate as any one reviewer, blinded or	Explore addi- tional applica-
	with sorting.	extractionj	non-blinded.	tions
	Large reviews		non binaca.	cions
	that have al-			
	ready begun			
	categorization.			
RobotReviewer to	Reviews of	Use as peda-	Equally as accurate as	Scale up imple-
assess Risk of Bias	RCTs	gogic tool,	one researcher. No re-	mentation
discussion of Dids		particularly	liable time estimates.	
		for newer re-		
A set a secol for the set	A 11	searchers	1	
<u>Automatic text</u> <u>clustering</u>	All	Single- or auto-screen-	In screening: 74% less time to screen when	
crustering			applied to the least rel-	tional applica- tions.
		de-prioritiza-	evant studies. In study	
		tion. Single-	5	Scale up imple-
		or auto-cate-	as accurate as one re-	mentation within
		gorization	searcher. 34% less	screening
		(data extrac-	time to categorize	5
		tion).	when semi-automated;	
			71% less time when	
			fully automated.	
	Review updates	• •	Retrieve fewer and	Librarians
<u>Graph (MAG)</u>		or replace	more relevant studies	proceed
		some data-	than traditional data-	
		base searcnes	base searches. Potentially replace one	
			or more database	
			searches.	
			sear circs.	

 Table 2: Overview of evaluated techniques, benefits, and recommendations

Explanation: RCT=randomized controlled trial, SR=systematic review.

### **Priority screening**

Priority screening learns from researcher screening decisions and pushes relevant studies forward in the screening queue (table 3). This technique does not make screening decisions, but helps researchers identify and handle included studies first.

Type of machine	Supervised, human-in-the-loop, active learning	
learning		
<b>Combination with</b>	Optimizes the subsequent use of custom classifiers	
other ML functions		
Review stage	Title and abstract screening	
Degree of difficulty	Easy	
Support needs	Low - Can be implemented independently with email sup-	
	port from EPPI or ML team	

	C 1
<b>Table 3:</b> Brief description of	f characteristics of priority screening

Five projects contributed to this evaluation:

- <u>Secure institutions for youth</u>
- <u>Understanding and helping children who resist or refuse postseparation parental</u> <u>contact</u>
- Systematic review of RCTs of treatment for perpetrators of sexual violence
- The relationship of travel distance to delivery institutions and accompaniment
- The effects of covid-19 on children and youth's wellbeing

#### How did we test the function?

- In the pilot project, we randomized 14,000 studies to be screened as usual (randomly) or using priority. Researchers tracked time spent, and we calculated inclusion rates after regular amounts of studies had been screened.
- Subsequent projects used priority screening exclusively (with no comparison to random screening) and we tracked inclusion rates at regular intervals.

#### What have we found so far?

- Time savings in the screening phase: 60% less time compared to screening as usual, if used until the inclusion rate flattens and then moving to single-screening (pilot study). 90% less time when used in combination with custom classifiers and switching to single- or auto-screening for studies under or over various cut-offs (see <u>Classifiers</u>).
- Efficiency: 95% of all included studies are found after screening 7.5-35% of retrieved studies. The more precise the PICO (and the more precise human screening), the more efficient priority screening is, and the quicker all included studies are identified.
- Other benefits: It requires precision of inclusion criteria immediately in the screening process, and therefore a clarification of misunderstandings earlier, both within the project team and between the project team and commissioner. It also allows projects to provide commissioners with estimates of project size quickly.
- Usefulness: Highly accepted by the teams that have used it.

Workflow changes that optimize benefits

- Priority screening necessarily changes existing screening workflows, and more than any other function we have evaluated. For example, the project team should sit together electronically or in person when screening the first 200 studies, and reconcile screening conflicts much more frequently and at regular intervals.
- Move to single-screening, and/or de-prioritize screening, after the inclusion rate plateaus. To maximize time savings, build a custom classifier.
- Begin full-text screening in parallel, as relevant studies are identified immediately.

## <u>Next steps</u>

• We are confident that priority screening can be implemented across all projects.

## Classifiers

Classifiers use natural language processing to predict membership of a piece of data (e.g. text in the title and abstract of a study) into one of two binary categories: "*A*" vs "*not A*" (table 4). For example, *include* vs *exclude*, or *population of interest* vs *not the population of interest*. "Pre-built" classifiers are those that have been trained and validated. "Custom" classifiers refer to any classifiers built by a user. Within EPPI-Reviewer, several pre-built classifiers are available, and users can build their own. We conducted three separate evaluations.

Type of machine learning	Supervised, human-in-the-loop	
Combination with other	Ideal after priority screening	
ML functions		
Review stage	Title and abstract screening, or data extraction	
Degree of difficulty	High. Requires both understanding of the ML process	
behind it, and high user skills in EPPI.		
Support needs	Our user guide can be followed. 60-120 min of ML	
	team support to help project leaders the first time.	

**Table 4:** Brief description of characteristics of classifiers to screen or categorize

## Custom classifiers for screening

This type of classifier is useful for all systematic reviews and health technology assessments (HTAs) with clearly defined research questions and inclusion criteria. It is not recommended for overviews of overviews, broad scoping reviews with multiple research questions, or for reviews with novel definitions of interventions, exposures, etc. The accuracy depends on model quality, which the ML team can help project leaders assess in order to proceed correctly.

Nine projects contributed to this evaluation: an update of a covid-19 rapid review, one EUnetHTA rolling collaborative review and two updates, three scoping reviews, three reviews of RCTs/cohort studies, and one overview of reviews.

How did we test the function?

- Review of RCTs: We built a custom classifier after having screened (using priority screening and pre-built classifiers) 13.5% of references. We auto-screened all studies <10% likely, then manually single-screened to quality control. Screeners tracked time.
- Review of cohort studies: We built a custom classifier after having screened 61% of references. We deprioritized and single-screened all studies <30% likely, while writing the report.
- EUnetHTA rolling review and covid-19 update: We built a classifier first after having screened the first 1000 studies, and at regular increments thereafter, and repeated during subsequent updates.
- The remaining studies contributed to a retrospective evaluation. In seven completed reviews, we trained classifiers using random samples of 50 and 100 studies, as well as the first 25 studies included and a random 25 excluded studies (balanced between included and excluded), applied these to the remaining studies, and compared classifications with actual screening decisions

## What have we found so far?

A <30% cut-off criteria is highly accurate to predict exclusion:

- Studies below this cut-off can be auto-screened as irrelevant.
- No studies included at full-text are lost.
- 18-90% fewer studies can be screened at title and abstract level.
- Studies included first by priority screening should be used to train the classifier. These classifiers performed better than models with larger but randomly chosen training sets.
- This applies to SRs with clear research questions and well-defined interventions or exposures.

There are significant time savings even using a more conservative cut-off:

- In practice: Auto-screening <10% relevant studies saved 48 hours (36% of total screening time), with complete accuracy.
- Retrospective estimates:
  - Auto-screening <10% and >90% relevant studies, saves 90% of screening time.
  - Single-screening <50% relevant studies saves 60-70% of screening time.
- This applies to systematic reviews with clear research questions and welldefined interventions or exposures.

When custom classifiers do not work:

• In broad scoping reviews with multiple RQs or novel definitions of exposure, the data was not good enough to create a strong model. 1-2% of included studies were missed using a <30% cut-off.

What do we need to do next to find out more?

• Evaluate in a qualitative evidence synthesis.

- Improve training materials to make new users more independent and to reduce training burden on the ML team.
- Scale up teaching of necessary basic ML knowledge, to reduce user threshold to use this technique.
- Consider making guidelines regarding a cut-off threshold that could be implemented in evaluated product types.

## Pre-built study design classifiers

This type of classifier is applied to identified studies to identify three specific study designs: RCTs, systematic reviews, and economic evaluations. We did not evaluate the economic evaluation classifier. These classifiers are already fully developed and validated.

The following projects contributed to this evaluation:

- Pilot and retrospective evaluation: <u>Systematic review of RCTs of treatment for</u> <u>perpetrators of sexual violence</u> (12,000 references, 1.5% included at title and abstract, 0.1% included at full-text). Prioritized study designs: systematic reviews, then RCT, then n-RCT.
- Retrospective evaluation: <u>Overview of reviews of remote patient monitoring</u> <u>RCTs</u> (3,000 references, 4.8% included at title and abstract, 0.1% included at full-text). Due to a complicated research question, this project involved assessing primary studies included within systematic reviews.

## How did we test the function?

- Pilot: We applied study design classifiers consecutively, according to prioritized study design: first the systematic review classifier, then RCT classifier. We prioritized screening of those classified as >50% likely. At the end of the project, we checked all included studies' classifier score to see if they had been captured by the relevant study design classifier.
- Retrospective evaluations: We retrospectively applied the relevant pre-built classifier(s) to screened studies in two reviews. We compared classifications to actual screening and inclusion decisions.

## What have we found so far?

- Highly accurate: Pre-built classifiers are excellent at identifying study designs, confirming previous research. In the pilot study, 100% of included RCTs were identified by RCT classifier (as well as two included n-RCTs).
- <30% cut-off is accurate to auto-screen and reduces screening burden: They can be trusted to auto-screen irrelevant designs using a <30% cut-off, with no relevant studies lost. In the retrospective evaluations, auto-screening would have reduced screening burden by 25-76% studies at the title and abstract level, and 2-63% at full-text level.</li>
- >50% cut-off is accurate to prioritize relevant designs. In the pilot study, 7 of 8 included studies were identified by the SR and RCT classifiers (the remaining study was a different study design and identified by a custom classifier). These were captured after having screened only 13.5% of 12,000 references.

#### Next steps:

- These are well-developed and there is no need for further internal evaluation.
- Improve training materials to make new users more independent and to reduce the training burden on the ML team.
- Scale up teaching of necessary basic ML knowledge, to reduce user threshold to use this technique.

## Custom classifiers for study categorization

This type of classifier is relevant for review updates, rolling/living reviews, and other large projects (3000+ studies). It categorizes studies based on titles/abstracts, which can be used as a direct form of data extraction, or as a sorting exercise in order de/prioritize or target screening or other actions.

The following projects contributed to this evaluation:

- <u>Covid-19 living map</u>: Studies were manually categorized according to title/abstract to at least one population and one intervention. Thousands of new studies each week required significant scaling up of activities.
- <u>EUnetHTA rolling collaborative HTA on rare medications for covid-19</u>: The team could not rely solely on priority screening, as rare medications were not being picked up and thus the algorithm could not learn to identify them. Neither could the team rely on manual screening, due to the amount of studies and the rolling deadlines.


### How did we test the function?

- Covid-19 living map: After categorizing 2,400 studies, we built custom classifiers to predict the 50 most common categories. 200 unscreened studies were randomized into 1 of 3 arms (2 researchers blinded to each other, fully manual; fully automated, with quality-control by 1 researcher; semi-automated, with 1 researcher non-blinded to the classifiers and 1 researcher as quality-control). Three researchers were randomly assigned studies within each arm. Precision, recall, and time were tracked.
- EUnetHTA rolling review: Classifiers were built to identify studies of prioritized rare medications that they team had not yet identified through priority screening. That is, classifiers identified studies of thematic relevance to prioritize for human screening, rather than identifying studies relevant for inclusion.

#### What have we found so far?

- 60-70% time savings in categorization compared to manual practice
- Successfully identified rare studies for further screening, which otherwise would not have been identified through priority screening
- Equal accuracy compared to manual practice (Figure 1)

## Figure 1: Accuracy of custom classifiers



What do we need to do next to find out more?

- Continue evaluation in future review updates or rolling reviews.
- Scale up implementation through teaching and training so that more project leaders can be independent.

## RobotReviewer to assess Risk of Bias

RobotReviewer is fully developed ML system that assesses the first four domains of Cochrane's Risk of Bias tool and extracts relevant text to justify each assessment (table 5). It is integrated into EPPI Reviewer, as well as a standalone web-based tool.

Type of machine	Semi-automated, human-in the-loop: the user can accept
learning	suggestions for domain assessments and attach text snip-
	pets or amend them.
<b>Combination with</b>	Not required
other ML functions	
Review stage	Risk of Bias assessment for RCTs
Degree of difficulty	In EPPI Reviewer: intermediate skills.
	In the web-based version: no skills needed, but this is a
	slower alternative to EPPI Reviewer, and users were less
	positive.
Support needs	Minimal: Follow our how-to guide at your own pace. The
	EPPI superuser can you help you if you get stuck.

Table 5: Brief description of characteristics of RobotReviewer to assess Risk of Bias

We tested RobotReviewer in two systematic reviews of RCTs involving six researchers.

- <u>Work-related interventions for people on long-term sick leave</u>: N=23 RCTs contributed 148 domains. Two experienced and two newer researchers. One researcher-pair used RobotReviewer within EPPI Reviewer; one pair used the RobotReviewer website.
- <u>Systematic review of RCTs of treatment for perpetrators of sexual violence</u>: N=3 RCTs contributed 12 domains. One experienced and one newer researcher. One researcher used EPPI Reviewer and the other used the RobotReviewer website.

## How did we test the function?

- RCTs were randomly assigned into two arms for assessment: RobotReviewer within EPPI Reviewer, or the RobotReviewer website.
- All researchers were able to see RobotReviewer's domain and text suggestions while they made their own (i.e. no blinding). We measured human changes to RobotReviewer's domains (160 in total), changes from individual human assessments to final assessments, whether RobotReviewer's extracted text was deemed correct by humans, and time spent by every human on every step (administration, training, individual assessment, reconciliation, etc). Each person was also asked to report their overall impressions of the utility of RobotReviewer.

### What have we found so far?

### Accuracy

- RobotReviewer was as accurate as any one researcher: researchers accepted 83% of RobotReviewer's assessments (133 of 160), and 81% (129 of 160) of each other's assessments.
- In 79% of domains, there was complete agreement between RobotReviewer's assessment, a human's assessment, and the final assessment after agreement with another human. In only 4% of domains did RobotReviewer underestimate bias. For all other domains, automated RoB was over-estimated.
- Text snippets were sufficient for 86% of domains (86 of 104). This means researchers did not have to extract text justifications for 86% of these domains.
- Human corrections to RobotReviewer did not correlate with human experience level (i.e. no sign of confirmation bias among newer researchers), or with reviewer order (i.e. no sign of confirmation bias among the first of two researchers).

## Time and resource use

- Using RobotReviewer in EPPI Reviewer took 40% less time than using the webbased version. However, time use varied substantially by individual, and estimates must be taken with caution. Time use did not vary consistently according to experience level, amount of human corrections to RobotReviewer, or even amount of human corrections during reconciliation.
- We did not evaluate time use without automation.
- Administration time without needing to train a team (1 leader, 2 members, 1 support/analysis person): 2.6 hours. Administration time when training was needed, for an entirely new project team: 5 hours.

#### Acceptance

• Newer researchers said the extracted text helped focus their attention to the relevant parts of the study to examine, and that this saved time. Experienced researchers were, at worst, ambivalent. No one was negative to using RobotReviewer in the future, particularly the EPPI integration.

• Most researchers are not interested in replacing one reviewer with RobotReviewer, but in adding RobotReviewer to the existing process of two reviewers.

What do we need to do next to find out more?

- Recommendation: Repeat this evaluation in two new social/welfare reviews.
- Recommendation: Explore adaptation to Cochrane's Risk of Bias version 2.
- Optional: If time saved compared to fully manual RoB assessment is of interest, repeat this evaluation in a large review; ideally with the same participants.
- Optional: repeat this evaluation and measure acceptance more systematically.
- Proceed with capacity-building by highlighting accuracy over time saved.

We have an ongoing manuscript reporting these results which will be submitted in the fall.

## Automatic text clustering

Clustering algorithms analyze the distribution of words, parts of words, or terms in titles and abstracts, then uses the specifications of the user to make clusters based on dis/similarity, with descriptive names (table 6). The references in a review are assigned to one or more automatically identified clusters, such that any two references within the same cluster are similar in some useful way, and any two clusters are dissimilar in some useful way. Each cluster's references, text (titles/abstracts), and search terms can be examined.

Type of machine	Unsupervised	
learning		
<b>Combination with</b>	When used to help screen irrelevant references: useful to	
other ML functions	precede with priority screening and custom classifiers	
Review stage	Title and abstract screening, data mapping, study categoriza-	
	tion, searching	
Degree of difficulty	Intermediate	
Support needs	High: ML team provides an introduction and is available for	
	troubleshooting. The user can follow EPPI's guides and con-	
	tact the NIPH EPPI superuser or EPPI Centre for support.	

**Table 6:** Brief description of characteristics of automatic text clustering

Automatic document clustering was tested across the following projects:

- Pilot project for study categorization: <u>Secure institutions for youth</u>, a systematic literature search with sorting.
- Pilot project for use in screening: <u>Systematic review of RCTs of treatment for</u> <u>perpetrators of sexual violence</u>
- The relationship of travel distance to delivery institutions and accompaniment

## How did we test the function?

• *Study categorization or data mapping*: We compared time use, precision and recall of manual study categorization (humans using human-designed categories), fully automated clustering (machine using machine-designed


categories), and semi-automated clustering (human using machine-designed categories), in a simplified systematic review. All 128 studies in a review were categorized by two humans manually. We then ran the clustering algorithm, and randomly assigned all studies to be either coded by a human researcher blinded to cluster assignment (mimicking two independent researchers) or by a human researcher non-blinded to cluster assignment (mimicking one researcher checking another's work); the gold standard was agreement by a third researcher. Finally, we compared the original cluster assignments to this gold standard.

• *Screening*: We applied auto clustering to half of all unscreened studies that had already been classified as irrelevant. One researcher screened as usual, while a second used the clusters to help screen. We tracked productivity.

#### What have we found so far?

Data mapping:

- Most of the machine-created clusters were meaningful and useful, and some overlapped with manual categories. Machine-created clusters also uncovered one category not identified by human researchers but it could not have been used to sort studies into the pre-determined categories.
- Equal accuracy: When humans categorized according to the auto clustering scheme, automated clustering had similar precision to both blinded and nonblinded researchers (e.g., 88% vs 89%), but higher recall (e.g., 89% vs 84%).
- No evidence of confirmation bias: Researchers blinded and non-blinded to the cluster assignments did not categorize differently.
- Time saved: Semi-automated clustering took 34% less time than fully manual categorization of 128 studies, including time spent making the categories/clusters to final agreement. Fully automated clustering took 71% less time (figure 2).



#### *Figure 2: Time used for categorzation of 128 studies (hours)*

Screening:

• Time saved: 74% less time used to screen irrelevant studies (383 excluded/20 min with clusters, including the time needed to make the clusters, compared to 100 excluded /20 min).

## Usefulness:

- Study categorization / data mapping: Ideal for simpler products (scoping reviews, systematic literature with sorting), to quickly become familiar with available data and uncover similarities and differences between studies.
- Screening: The more studies to screen, the more useful auto clustering is. It is particularly useful to screen or auto-screen irrelevant studies near the end of the priority screening process.
- Norwegian studies can be clustered.
- References without abstracts (often grey literature) are difficult to cluster.

## What do we need to do next to find out more?

- For use in screening: test in 1-2 more projects with large amounts of studies, to confirm time saved. Randomize half of studies to be screened as usual, and half to be clustered and then screened.
- For use in search term identification: a librarian team should evaluate usefulness of automatically vs manually identified terms, in a finished search strategy.
- Clustering is a well-known ML technique. We should explore other innovative ways of applying auto clustering to systematic reviews, e.g. sampling within QES.
- Scale up implementation.

A manuscript reporting these results has been accepted upon minor revisions to *Research Synthesis Methods*.

## Microsoft Academic Graph (MAG)

Microsoft Academic Graph (MAG) is an online database and knowledge graph of 260 million scientific publications, featuring a novel data structure that is based on advanced neural network machine learning (table 7). With MAG, researchers are able to search for research semantically, similar to searching in Google, and research is linked using an iterative, machine-learning-created hierarchy of 700,000 topics – rather than having to identify research based on keywords or database-specific terms.

Within the EPPI software it is possible to use a selection of articles as a starting point to conduct literature searches of the whole database, by requesting the retrieval of similar studies. Hence the tool provides the option to update a review or supplement a search, based a previous version's included studies or an already included batch of studies from a single database.

In May 2021, Microsoft announced that the Microsoft Academic website will be retired on December 31, 2021. Although this means that introducing MAG searches more widely is not sensible, gained experience supports the use of semantic/neural network searches, which are being developed by other players in the field (Google Scholar, Web of Science, and Scopus). Our gained experience will be of relevance when evaluating usefulness of other service provider's search functions in the future.

, <u>,</u>	
Type of machine learning	Neural network
Combination with other	Priority screening, custom classifiers
ML functions	
<b>Review stage</b> Searching, title and abstract screening, review up	
	ing
Degree of difficulty	Low
Support needs	N/A – Librarians proceed

Table 7: Brief description of characteristics of Microsoft Academic Graph

We evaluated this function in the following projects:

- Long covid
- <u>Risk factors of covid (4<sup>th</sup> update)</u>
- <u>EUnetHTA rolling collaborative review of rare medications (3<sup>rd</sup> update)</u>
- An ongoing librarian evaluation led by Lien Nguyen

## How did we test the function?

- Covid projects: We used MAG as a supplementary database for an update or to complement a simple search within a review. We used priority screening to immediately identify relevant studies following database searches, then entered the included studies into MAG, and retrieved relevant studies back.
- EUnetHTA and librarian evaluation: We compared overlap between MAG and traditional database searches, to identify if studies were identified by only one of the two sources.

## What have we found so far?

- MAG's retrieved studies are 3-6 times more relevant compared to a single database's retrieved studies, both at title/abstract and full-text level. MAG provided 23-50% of the studies included at full-text.
- MAG retrieves up to 85% fewer studies compared to a single database search.
- In one project's update (EUnetHTA), MAG failed to identify one included study at full-text that the traditional search identified, due to a 4+ week lag after journal publication. In the librarian evaluation, MAG retrieved all included studies.

What should a librarian team do to find out more?

- Identify alternatives to MAG, due to MAG shutting down in December 2021.
- Measure overlap between our commonly used databases and MAG (or MAG alternatives), to reduce searching in superfluous databases/sources.
- Assess whether a traditional literature search can be replaced by searching exclusively in MAG.
- Repeat this evaluation in social/welfare reviews.

- Repeat this evaluation in different review sizes, to estimate a threshold for when it is enough to search in/with MAG only.
- Explore MAG's potentials in grey literature searching, which is known to be time consuming.
- Explore the potential implications of MAG (and its alternatives) to our conventional approach to searching. We need to be prepared for the next alternative, so that we can quickly implement and evaluate its functions.

### Collaboration outside of the ML team

Part of the team's work was to assess possibilities for collaboration, nationally and internationally.

### National Institute for Health Care Excellence and EPPI Centre

We initiated a study with NICE and EPPI Centre to improve the priority screening algorithms within EPPI. Each organization has contributed RIS files of completed projects, and NICE and EPPI programmers are running simulations with new algorithms. This study (k > 100 projects) is the largest simulation study of ML approaches with screening, and results will be used to suggest stopping criteria for screening, or when researchers can stop manual screening.

### **University of North Carolina**

We exchange researcher-oriented ML user guides and feedback with the University of North Carolina's information specialists, who hold responsibility for ML activities within evidence synthesis.

#### NIPH

We initiated talks with: Divisions for Mental and Physical Health, Health data and digitalization, Infectious Diseases, and IT.

We have reached out to researchers across the NIPH to map ongoing ML activities and interests, and held a one-hour networking meeting on 23. June 2021. The meeting goal was to be a springboard for knowledge transfer and collaboration beginning simply by communicating, as it appears that ML activities are siloed within both divisions and projects. We identified overlapping activities and drivers, and are working on next steps.

## **Dissemination outputs**

#### User-friendly summaries of machine learning functions

We created 1-page, user-friendly summaries of each ML function. They were developed to help project leaders understand the different functions, when to use them, and how to combine them.

### User guides adapted to NIPH workflows

See Appendix for information on user guides.

One remaining assignment that we suggest continuing with in future projects is producing template language about ML for project leaders to use in protocols and reports. Text has already been extracted from all published protocols and reports but needs to be transformed into template suggestions as well as integrated into the NIPH handbook for systematic reviews.

### Manuscripts

Muller AE, Ames HMR, Jardim PSJ, Rose CJ (revision submitted and under review). Comparing automated text clustering with Lingo3G and human research categorization in a rapid review. *Research Synthesis Methods*.

Jardim PSJ, van de Velde S, Rose CJ, Ames HMR, Meneses Echavez JF, Himmels J, Muller AE (in progress). A user-centered study of automating risk of bias in real-life systematic reviews.

Røst T, Slaughter L, Nytrø Ø, Muller AE, Vist GE (in press). "Using neural networks to support high-quality evidence mapping". *BMC Informatics*.

### Presentations

Members of the team gave a number of presentations during spring 2021 (table 8).

Date	Presentation title	Context and audience
02.02.2021	Drøfting av planer og ak- tiviteter lag for maskin- læring	Leader team, Cluster for Reviews and Health Technology Assessments
3.03.2021	Microsoft Academic Graph	Librarian <i>faggruppe</i>
23.02.2021	Testing out Microsoft Academic Graph in covid-19 rapid reviews	Citation networks in literature search - web conference, Norwegian Scientific Commu- nity for Food and Environment
15.03.2021	Getting to know the ma- chine learning team – who we are and what we are working on	Ukestart meeting, Division for Health Ser- vices
06.04.2021	Midtveis rapport	Leader team, Cluster for Reviews and Health Technology Assessments
26.04.2021	Results of a prospective user study of RobotRe- viewer	Project leaders and members who partici- pated in the user study in the Cluster for Re- views and Health Technology Assessments
08.06.2021	Scaling up machine learning with a dedi- cated team	Network meeting of evidence synthesis or- ganizations: NIPH, NICE (UK), EPPI Centre (UK), ICQIG (Germany), SBU (Sweden),

Table 8: Overview of presentations delivered by the ML team

		CADTH (Canada), Cochrane, Cochrane Neth- erlands, MAGICapp
25.05.2021	Proposal for a ML strat- egy	Leadership group, Cluster for Reviews and Health Technology Assessments
21.06.2021	Hvor mange roboter trenges for å vurdere Risk of Bias?	Ukestart meeting, Divsion for Health Ser- vices
23.06.2021	Introduction to HTV's ML team	Network meeting on machine learning and big data: representatives from all divisions + IT
2.11.2021	5 oral presentation ab- stracts submitted; no de- cisions yet about ac- ceptance	CADTH online conference: "Uncertain Times, Imperfect Evidence, and the Impera- tive to Act"

### **Strategy-related outputs**

We developed a proposal for a machine learning strategy for the Cluster for Reviews and Health Technology Assessments. The full strategy is presented in a separate document.

We also proposed a text for NIPH's revised strategic priorities. The following text was submitted to the management in the Division for Health Services in May 2021:

"Context: There is an increasing demand from users for high-quality products delivered faster, with greater efficiency, and at lower cost. There is also a growing societal need for high-quality, understandable, and accessible knowledge. Furthermore, rapid developments in the types of data and advanced methods available are opening opportunities to increase efficiency and speed without compromising on quality. With the revision of the strategy document, we have the opportunity to develop a clear, cross-division commitment to ML and methods innovation that can facilitate the systematic identification and implementation of tools and strategies to benefit a wide variety of products across the institute.


The problem: We have identified machine learning (ML), big data, and advanced analyses included directly or indirectly within several different strategic priorities in the 2019-2014 institute strategy.

- Forutse helsetrusler
- Stor data og avansert analyse
- Sanntidsovervåking
- På tvers av sektorer
- Enklere navigasjon
- Helsedata skal komme til nytte

But these strategies don't appear particularly coordinated or connected – which very likely means untapped opportunities for knowledge transfer, capacity-building, innovation, and de-duplication of work. For example, Jon Bohlin (Smittevern) uses machine learning in epigenetic modelling, Christian Madsen (Psykisk og fysisk helse) to predict maternal outcomes, and Yungsung Lee (Pyskisk og fysisk helse) to predict biological age based on blood samples – similar techniques can be used in vaccine development and in epidemic modeling.

The solution:

- An institution-wide vision: FHI will be an innovative organization that uses machine learning, automation, and big data to deliver our high-quality products (kunnskap, beredskap, and infrastuktur) more effectively, while also increasing accessibility, and sustainability.
- An institutional strategy that brings together the currently disjointed and vertical activities into a more cohesive, mutually beneficial and innovationoriented collaboration. FHI products (kunnskap, beredskap, infrastuktur) will be stronger if we can facilitate in-house knowledge transfer and coordination. Based on our networking regarding only machine learning, we see quite a lot of internal expertise that can be exploited, as well as numerous opportunities for external collaboration and capacity-building.
- A Center of Excellence for knowledge innovation for machine learning, automation and big data. This will draw together/centralize/coordinate ongoing machine learning, other advanced methods, and workflow optimization projects involving arbeidsflyt, automation, and dating sharing, currently localized in Områder for smittevern, helsetjenester, helsedata og digitalisering, psykisk og fysisk helse, and IT (See figure for an example of the ongoing machine learning activities).



*Figure: A rapid mapping of current Machine learning activities (The yellow color represents ongoing activity)* 

The potential: Synergies that directly benefit existing strategies (see above).

- Through coordinating område-specific activities, internal expertise will be identified and strengthened, and thereby made available for future development.
- Increased efficiency and speed of production, while maintaining/improving quality, in the involved projects and knowledge products. Some examples: faster evidence synthesis in Område for helsetjenester, advanced epidemiological studies in Område for psykisk helse, rapid covid-19 modelling in Område for smittevern.
- Resources and time saved can be 'banked' back into development/innovation efforts.
- This center, and FHI in general, could become a model for other public health institutions (strategic priority: 'Norge i verden'). Through prioritizing ML innovation, we can demonstrate the implementation and success of cross-sectoral, horizontal programs rather than vertical, siloed initiatives."

## **Lessons learned**

We managed to spark interest in ML, and successfully recruited and trained several project leaders and members to apply newly learned methods. Sole one-on-one trainings were, however, not sufficient for immediate method independence. To address this, educational and how-to guides were developed, and in the future, a new constellation of the ML team with more employees involved in distinct short-term roles will support scalability.

This team – initially mostly ML-novices – matured to internal training and implementation experts, through 4-5 weeks of internal capacity-building and peer-teaching. This was a sunk cost and delayed the start of other activities, although served the additional purpose of team-building. For future iterations of the team, recruiting employees with existing skills in ML and software within evidence synthesis would minimize large upfront costs.

Blocking out team members' time allowed them to prioritize ML tasks, which were often naturally de-prioritized in the face of other commissions. Related to this, team members also needed to feel confident that risk-taking was allowed and encouraged; for example, testing out a ML function in a new software for several hours and concluding that it had limited utility was still a valuable use of time.

It is crucial that the ML team continues to recruit "early adopters": employees interested in ML and innovative methods, and willing to adopt and spread new skills and knowledge. It is equally important that the team be critical and aware of ML's limitations, but such constructive criticism should be provided by team members or advisors with ML experience, not by ML-naïve/skeptic team members.

To support ML adoption and acceptability, in-house evaluations can be used, including well-developed and already validated techniques. Involving interested project leaders in the design of these evaluations may also increase subsequent acceptability. These evaluations can also be used to experiment with workflow modifications. The more workflows are changed, the more important it is that project teams feel ownership of or inclusion in those change decisions.

Home-grown, Norwegian-language training materials were popular.

ML can be a disruptive technology within evidence syntheses, although it does not have to be. The time savings we have seen in various phases of our reviews can be received 27

as positive, as well as threatening to one's usual role and responsibility, or both. We hope that our suggested format of the future team, with rotating short-term members will build trust in ML, but this is not a given: a goal should be to expose as many employees as possible to ML, while ensuring that concerns are heard and addressed.


# Appendices

Appendix 1: How to put up a priority screening in EPPI-reviewer

Appendix 2: Machine learning classifiers – how to build your own in EPPI 4

Appendix 3: Risk of Bias assessments with machine learning – Team leaders

Appendix 4: Risk of Bias assessments with machine learning – Team members














	EPPI-Reviewer Web (Beta)		
Username:	brukernavn	0	
Password:		E	
Login	Forgot Password?	to Create	
ý	Visit the <b>EPPI-Reviewer Gateway</b> for Account and Review Management, Documentation, Support and the RIS ex	port utility.	
	For Cochrane Authors: click HERE to login with your Cochrane	account. More info	
	Version: 4.12.0.0	24. mar. 2021	

CENTRAL Bets	Feedback Help Lien Nguyen	Logout
Welcome to EPPI-Reviewer Web (beta).		
This <b>Beta Application</b> provides an alternative interface to many common functionalities available in <b>EPPI-Reviewer 4</b> . It works in modern web browsers and no longer requires the Silverlight plugin so it can be used on different devices such as desktops, laptops and tablets. Since it operate same data as EPPI-Reviewer 4, you can work on the same review using <i>either</i> application. Although we are continuously adding more functionality to this version you may still need to to use the older Silverlight application for some functions, until they are add new version.	DEVIEW	P   ER
We encourage all users to provide feedback and suggestions by contacting EPPISupport@ucLac.uk.	Create Re	view
		\$




CEEPEI Beta	
Welcome to EPPI-Reviewer Web (beta).	
This Beta Application provides an alternative interface to many common functionalities available in EPPI-Reviewer 4. It works in modern web browsers and no longer requires the Silverlight plugin so it can be used on different devices such as desktops, laptops and tablets. Since it operates on the same data as EPPI-Reviewer 4, you can work on the same review using <i>either</i> application. Although we are continuously adding more functionality to this version you may still need to to use the older Silverlight application for some functions, until they are added to the new version. We encourage all users to provide feedback and suggestions by contacting EPPISupport@ucl.ac.uk.	
Review name & ID-number srtools-support@fhi.no Brukerveiledning v. 1.0 ©2021	



eview home References Frequencies Crosstabs	Search & Classify C	ollaborate	
Review Items Import Items  Manage Duplicates Upda	ate review		REVIEW HOME (Startside)
Included: 2905 Excluded: 0	Deleted: 186	Duplicates: 109	
			The Screening List is Enabled and Ready: Click Here to start screening.
Coding Progress Coding Tools  Coding Tools			Your account expires on: 15. des. 2021 Current(shared) review expires on: 15. des. 2021.
👗 Screen on Title & Abstract	<b>Ø</b> 31	• 0	Create Review
2 Screen on Full Text	<b>Ø</b> 15	• 0	
2 Screen T/A, Fear SR	<b>3</b> 17	• 0	
Standard Tools:			
2 Risk Of Bias (Cochrane)	<b>O</b> 0	• 0	
2 Data Extraction	<b>Ø</b> 0	• 0	
A NTRK	<b>Ø</b> 417	• 0	
Administration Tools:			
2 Allocations	<b>O</b> 0	• 0	
Retrieval status	<b>O</b> 0	• 0	

eview home References Frequencies Crosstabs	Search & Classify Col	laborate	
Review Items Import Items Manage Duplicates Upd	late review		REVIEW HOME
Included: 2905 Excluded: 0	Deleted: 186	Duplicates: 109	Importere referanser
Coding Progress Coding Tools			Likk på Import Items
Screening Tools:			Your account expires on: 15. des. 2021 Current(shared) review expires on: 15. des. 2021.
2 Screen on Title & Abstract	<b>Ø</b> 31	• 0	Create Review
2 Screen on Full Text	<b>©</b> 15	• 0	
2 Screen T/A, Fear SR	<b>Ø</b> 317	• 0	
Standard Tools:			E
2 Risk Of Bias (Cochrane)	<b>O</b> 0	• 0	
2 Data Extraction	<b>Ø</b> 0	• 0	
1 NTRK	❷ 417	• 0	
Administration Tools:			
2 Allocations	<b>©</b> 0	• 0	
2 Retrieval status	<b>Ø</b> 0	• 0	•




			SOURCES in Review:	Close/back
nage Sources Import Items PubMed	×		SR Fear for import.bt	
itep		Import	tere referanser	4 PM
Organiser * Ny mappe	⊫ • <b>□</b> ()	n kli	ikk på Import Items	2 AM
RIS V S Denne PCen Navn Endringsdato	Type Størrelse			
ick th > 3 3D-objekter	RIS-fil 284		elg RIS-fil	
> B Dokumenter		🗆 Kli	kk på Select File	
> ♪ Musikk > ♣ Nedlastinger		🗆 La	st opp RIS-fil fra EndNote-bibliotek	τ.
> Viterasinger			Mental health MAG (Jan) Selected items from MAG on 2/11/2021 at 11	
> U OSDisk (C)			Selected items from MAG on 2/11/2021 at 1 Selected items from MAG on 2/11/2021 at 3:	
> 👟 Fellesområde on > 👞 Fijemmekatalog			SR fear 18 included from map.txt	
> Ser Fijermekatalogi > Ser Ordinær Sone (N * K	>		Automated search: 3/10/2021 at 2:57:58 PM	
Filnavn:	Egendefinerte filer (*.txt;*.ris) ~		Automated search: 3/10/2021 at 3:45:51 PM	
2	Apne Avbryt		Lien og Marit test 12.03.21.txt	
			TestMAG_20210406.txt	
			Tannpleie_MAG-test.txt	
			Tannpleie_ALLE_EPPI-test.txt	
			Automated search: 4/13/2021 at 2:58:28 PM	
			Microsoft Academic search: AND(#15, #16)	


REAL RELATION OF THE RELATION	Import/Mana	ge Sources Feedback (Heys Lien Nguyen Logout SOURCES in Review: Close/back
lanage Sources Import Items PubMed		No Sources in review.
Step 2: Preview and import:         back       Show Preview         Results: Total references = 101         Source Name         citation-export.ris         Search String (optional)         Database (optional)	Date of search 22-May-2021	Importere referanser Klikk på Import Items Velg RIS-fil Klikk på Select File Last opp RIS-fil fra EndNote-bibliotek Fyll ut info for enklere gjenfinning
Description (optional)		
Notes (optional)		

Beta	Import Items	PubMed		SOURCES in Review No Sources in review		Close/back
Step 2: Previe           back         Show           back         Show           cesults: Total refs         Source Name           citation-export         Source Name           control of the source Name         Source Name           Database (option         Option           Description (option         Source Name           Notes (optional)         Source Name	erences = 101 .ris titional) hal) onal)	t:	Date of search 22-May-2021	0	EndNote-bibliotek e gjenfinning for å komme	<i>b</i>
Import						

Review home References Frequencies Crosstabs	Search & Classify	Collaborate	
	ite review		
Included: 2905 Excluded: 0	Deleted: 186	Duplicates: 109	Fjerne dubletter
Coding Progress Coding Tools			Klikk på Manage Duplicates
Screening Tools:			Your account expires on: 15. des. 2021 Current(shared) review expires on: 15. des. 2021.
🤱 Screen on Title & Abstract	<b>Ø</b> 31	• 0	Create Review
🤱 Screen on Full Text	<b>Ø</b> 15	• 0	
🤱 Screen T/A, Fear SR	317	• 0	
Standard Tools:			
🤱 Risk Of Bias (Cochrane)	<b>Ø</b> 0	• 0	
2 Data Extraction	<b>O</b> 0	• 0	
2 NTRK	<b>Ø</b> 417	• 0	
Administration Tools:			
1 Allocations	<b>Ø</b> 0	• 0	
🤱 Retrieval status	<b>O</b> 0	• 0	

PPI REVIEWER Beta			Duplicate	s		Lien Nguyen Logout
one?	Tools	Refresh Get New Duplic	ates Mark Automatically	<b>0</b> groups of possible of	duplicates loaded (0 marked as completed).	Close/back
oner	ID Short Title	Please click on a good	up to see the group details.	F	jerne dubletter	
Status: Norma	al. Last code update: 20/05/2021	Current User: Lien Nguyen	Review: Lien test med Elisabet			
					Klikk på Get New Duplicates	









OPPI EPPI-Reviewer	
CENTRE LOGIN	
HURE RELP EPH-HAPPER HIS EXPORT ABOUT ACCOUNT AUTORS	_
Account and Review Manager	
Status: Status: Normal.	
If you already have an EPPT Reviewer 4 account please dick on Login.	
Login Access an existing account	
Errora our Password? Forgot vour Usemame? Need to activate your account?	
If you do not have an EPPT-Reviewer 4 account you can create one by clicking on New account.	
New account Create a new account	
If you are creating a trial account please see About trial access.	
Copyright 2021 by EPPE-Centre :: Privacy Statement :: Terms Of Use :: Site Map :: Login	
Home ::: Help ::: EPPI Mapper ::: RSI Expert ::: About ::: Acount Homager	
Brukerveiledning v. 1.0 ©2021	

22 May 2021 Cearch	
DECOUNT MANAGER	
Account and Review Manager	
Please enter your Username and Password Username Drukemann Password Password Loon Ecrypt. Password? Ecrypt.your Username? Need to activate your account? New account screen If you are creating a trial account please see About trial access.	×
Copyright 2021 by EP91-Centre :: Privacy Statement :: Terms Of Use :: Site Plap :: Login	
Brukerveiledning v. 1.0 ©2021	

Account Manager	
Account and Review Manager EPPI-Reviewer 4 manager	
Summary Purchase Utilities Site license Logout	
Summary Reviews Summary of you, ccount(s)	_
Your account summary Please note that all dates are dd/mm/yyyy	
ContactID Name Email address Last login Logged in (hrs) Account created Expiry date	Edit
15944 Lien Nguyen lien.nguyen@fhi.no 22 May 2021 20:57 29 11 Feb 2021 15 Dec 2021 In site License (ID:	0:68) Edit
Your credit purchases You do not have any credit purchases.	
Accounts you have purchased You have not purchased any other accounts	
You are logged in as: Lien Nguyen	
If you are creating a trial account please see About trial access.	
Copyright 2021 by EPPI-Centre :: Privacy Statement :: Terms Of Use :: Site Map :: Login	
Home :: Help :: EPPI-Mapper :: RIS Export :: About :: Account Manager	

		-Review	/er					May 2021		
CENT		Review								
CENT	LOGIN									
-				OME HELP	EPPI-MA	PPER RIS EX	PORT	ABOUT	CCOUNT N	
ount Manager										
ccount	and Review	v Manager								
PPI-Review	ver 4 manager									
	_									
Summary	Purchase	Utilities Sit	e license 🛛 Log	gout						
Summary	Reviews									
Summary	of your reviews									
Shareable	reviews rou have	purchased or ha	e administrativ	e rights to						
ReviewID			login by this	Expiry da	te					Edit
	review crea	5010				ense 'NORWE	CTAN IN			
	Controlled 25 N	ov 2020 06 M	ay 2021 15:39	HEALTH ' (		LEIDE NORWE	ODAIN THE	STITUTE OF F	Oblic	Edit
										25
Your non-	shareable reviews	(you create non-st	areable reviews v	within EPPI-R	eviewer 4)					2
ReviewID	Name of review	v				Date		gin by this	Edit	
						created 06 Apr 2021	22 May		C 414	
	Lien test med El	cabat								
27304 26506	Lien test med El Lien Nguyen's er	sabet tample non-shareat	le review			11 Feb 2021				
27304			le review							
27304 26506		ample non-shareat								
27304 26506 Other shar	Lien Nguyen's er	ample non-shareat		w created			27 Apr		Edit	v
27304 26506 Other shar ReviewID 26223	Lien Nguyen's er reable reviews you Name of review EUnetHTA RCR	ample non-shareal a are a member o Review owner Stijn Van de Vel	Date review	8	Last login 06 Apr 202	11 Feb 2021 by this revie 1 11:26	27 Apr	Remove fro	Edit	v
27304 26506 Other shar ReviewID	Lien Nguyen's er	ample non-shareat	Date review	D	Last login	11 Feb 2021 by this revie 1 11:26 21 14:34	27 Apr	Remove fr	Edit	v

							22 May	2021 Search
OP	PI EP	PI-Revi	ewer					CSPar Class
CE		GIN						
	_		но	ME HELP	EPPI-MAPPER	RIS EX	PORT ABO	UT ACCOUNT MANAG
ount Manag	jer							
ccour	nt and Rev	view Manag	er					
PPI-Rev	ewer 4 manage	er						
Summ	· ·	e Utilities	Site license Logo	ut				
Summa								
and the second second	ry of your revi							
Review	Name of	Date review	r have administrative Last login by this	Expiry date				Edi
25587	MAG		neviewer	15 Dec 2021 In HEALTH ' (ID:6		e 'NORWE	GIAN INSTITU	
	Controlled			HEALIH (ID:0	0)			
Review #						-	-	
Review t		ntrolled			00.0	011		
	Cancel/close		Ph	ority screenin	g O On @	OII		
BL codes		. Condimitation						
BL codes		Send invitation	Email	Last access	Coding	Read only	Review admin	Remove from review
BL codes Member Contact	s of this review Reviewer (e)			Last access 06 May 2021 15:29				
BL codes Member Contact ID	s of this review Reviewer (ex Marit Johanser #68	xpiry date)	marit.johansen@fhi.no	06 May 2021	only	only	admin	review
BL codes Member Contact ID 10426	Reviewer (ex Marit Johanser #68 Ingrid Harboe #68	piry date) n () In Site License () In Site License	marit.johansen@fhi.no	06 May 2021 15:29	only	only	admin	review Remove
BL codes Member Contact ID 10426 11210	Reviewer (ex Marit Johanser #68 Ingrid Harboe #68 Gyri Hval () In	piry date) n () In Site License () In Site License	marit.johansen@fhi.no ingrid.harboe@fhi.no gyri.hval@fhi.no	06 May 2021 15:29 Never	only	only	admin	Remove Remove

	PI EPPI-Revi					22 May	2021 Search		
e	LOGIN		ME HELP E	PPI-MAPPER	RIS EX	PORT ABOL		ER-	
Account Mana	nt and Review Manag	er							
EPPI-Rev.	iewer 4 manager ary Purchase Utilities								
		2							
	rs email address a nt is valid it will b 25597 THE MAG Controlled	and select I		ew an	d an	email	send to th	e accour	nt hol
the accou	nt is valid it will b	and select In be placed in	nvite.			email	send to th	e accour	nt hol
the accou	nt is valid it will b 2597 tte MAG Controlled Cancel/dose s of this review Send invitation	and select In be placed in	n <b>vite</b> . the revi			Review	Remove from	e accour	nt hol
the accou Review t Save BL codes Member Contact	nt is valid it will b 2597 tte MAG Controlled Cancel/close s of this review Send invitation	and select In be placed in Pri	nvite. the revie	On @ (	Off			e accour	nt hol
the accou Review t Save BL codes Member Contact ID	nt is valid it will b	and select In be placed in Pri	Invite. the revie fority screening	On @ (	Off	Review admin	Remove from review	e accour	nt hol
the accou Review t Save BL codes Contact 10 10426	nt is valid it will b 25587 Kitle MAG Controlled Cancel/close s of this review Send invitation Reviewer (expiry date) Marit Johansen () in Site License #Gent Hartbo () in Site License	e placed in Pri Email mart.johansen@fhi.no ngrid.harboe@fhi.no	Invite. the revie fority screening	On @ (	Off	Review admin	Remove from review Remove	e accour	nt hol
the accou Review Save DL code DC code 10426 11210	nt is valid it will b AG Controlled Cancel/close s of this review Send invitation Reviewer (expiry date) Mark Johansen () in Site License #68	Email mart.johansen@fhi.no ngrid.harboe@fhi.no gyn.hval@fhi.no	Invite. the reviewed tority screening Last access 06 May 2021 15:29 Never	On @ (	Off	Review admin	Remove from review Remove Remove	e accour	nt hol



								22 Ma	y 2021 Search
1	OP	PI E	PPI-Rev	iewer					
(	CEN	TRE	OGIN		OME HELP	EPPI-MAPPER	DIC E	XPORT ABC	
	count Manag				OME HELP	EPPI-MAPPER	RIS E	APORI ABU	ACCOUNT MANA
			eview Manag	ger					
	EPPI-Revie	ewer 4 mana	ger						
	Summa	ny Purcha	ase Utilities	Site license Log	jout				
	Summar							_	
		ry of your rev							
	ReviewI	Name of	Date review	or have administrativ Last login by this	Expiry date				Edi
		MAG	created	reviewer		n Site Licens	e 'NORWE	GIAN INSTIT	
	25587	Controlled	25 Nov 2020	06 May 2021 15:39	HEALTH ' (ID:				Edi
	Review #	25587							
-	Review til		Controlled						
2	Save	Cancel/close		р	riority screenin		$\frown$		
	BL codes		ew Send invitation			> (	<b>1</b>		
	Contact		expiry date)	Email	Last access	Coding	Read only	Review admin	Remove from review
	10426	Marit Johans #68	sen () in Site License	e marit.johansen@fhi.n	06 May 2021 15:29			1	Remove
	11210	Ingrid Harbo #68	oe () in Site License	ingrid.harboe@fhi.no	Never				Remove
	15367	Gyri Hval ()	In Site License #68	gyri.hval@fhi.no	Never				Remove
	11288	Ley Muller ()	) in Site License #68	aemu@fhi.no	06 Apr 2021 09:53				Remove

CONTRE EPPI-Reviewer	HOME HELP EPPI-MAPPER RIS EXPORT	18 May 2022 Search	
Getting Started EPPI-Reviewer is an application for all types of literatu analyses, 'narrative' reviews and meta-ethnographies. (with some of our existing reviews containing over a r	It is suitable for small or large-scale reviews	News Microsoft Academic Graph EPPI Reviewer is Integrating	
Start using EPP1-Reviewer today! Sign up for a free one month trial!	Please see About our fees and About support for further information.	access to 230 million OA bibliographic records of research articles, connected in a large network graph of concept & citation reliationships: the Microsoft Academic Graph (MAC) - updated weekly.	
EPPI Reviewer Web is the latest version of our soft without the need for any add-ons or other installation smartphones and tablets - useful for screening on the	. It works across web-enabled devices including movel  ER Web login -:	WWCS 2020 We presented our Evidence Mapping Tools at the What Works Global Summit 2020 Click to find out more	
Advances Advance	EPPIReviewer Web  We are always improving and refining the software and you can find details in our "Latest Changes" forum post.	New Videos for ER Web! Great for those new to EPPI Reviewer or switching from EPPI Reviewer 4.	

CERVENCES	Beta	Feedback Help Lien Ng	uyen Logout
	Welcome to EPPI-Reviewer Web (beta).		
It works same da Althougi new vers	urage all users to provide feedback and suggestions by contacting EPPISupport@ucl.ac.uk.	Ided to the	PPI VIEWER
ID	Review Name Velg review	Last Access: 👃	Coding UI
25168	Test MAG	18. mai 2021	Coding UI
25587	MAG Controlled	10. mai 2021	Coding UI
26506	Lien Nguyen's example non-shareable review	27. apr. 2021	Coding UI
26223	EUnetHTA RCR	6. apr. 2021	Coding UI
27304	Lien test med Elisabet	6. apr. 2021	Coding UI

eview home References Frequencies Crosstabs	Search & Classify	Collaborate	
Review Items         Import Items<	ate review Deleted: 186	Duplicates: 109	REVIEW HOME (Startside)
Coding Progress Coding Tools			The Screening List is <b>Enabled and Ready</b> Click Here to start screening. Your account expires on: 15. des. 2021
Screening Tools:	<b>Ø</b> 31	• •	Current(shared) review expires on: 15. des. 2021.
Screen on Full Text	© 15	00	
Screen T/A, Fear SR	317	• 0	
Standard Tools:			
2 Risk Of Bias (Cochrane)	<b>Ø</b> 0	• 0	
2 Data Extraction	<b>Ø</b> 0	• 0	
1 NTRK	❷ 417	• 0	
Administration Tools:			
2 Allocations	<b>O</b> 0	• 0	
2 Retrieval status	<b>O</b> 0	• 0	

eview home References Frequencies Crosstat	os Search & Classify	Collaborate	
Review Items Import Items  Manage Duplicates	Update review	1	Fordele referanser
Included: 2905 Excluded: 0	Deleted: 186	Duplicates: 109	Klikk på Collaborate
			The screening corts channed wink newsy. Encounter to start socialing.
Coding Progress Coding Tools			Your account expires on: 15. des. 2021
Screening Tools:			Current(shared) review expires on: 15. des. 2021.
2 Screen on Title & Abstract	<b>Ø</b> 31	• 0	Create Review
2 Screen on Full Text	15	• 0	
🚊 Screen T/A, Fear SR	<b>Ø</b> 317	• 0	
Standard Tools:			Ľ
2 Risk Of Bias (Cochrane)	<b>O</b> 0	• 0	
2 Data Extraction	<b>Ø</b> 0	• 0	
1 NTRK	<b>Ø</b> 417	• 0	
Administration Tools:			
2 Allocations	<b>O</b> 0	• 0	
2 Retrieval status	<b>O</b> 0	• 0	

iew home References Frequencies	Crosstabs Search & Classify Collabo	orate				
tevic, yvers D Name Name S944 Lien Nguyen	Create new code     Create coding assignment       Coding Assignments     Id       Id     Name       Study:     No records available.	Group Codes to	Fordele referan Klikk på Col Klikk på Scr	llaborate		Collapse
omparisons des applied from this set Re	iewer 1 Reviewer 2 (Rev	viewer 3) (Only with this co	ode) D	ate Quick Rep.	Details	Collapse
			ode) D	ate Quick Rep.	Details	
des applied from this set Re			ode) D	ate Quick Rep.	Details	

evening Distribute Work Create reference groups ou can setup and review your screening setting 1. Via the guided steps wizard (preferred) 2. By viewing progress and then editing all so Setup Wizard View Progress and Status	is in two ways:	signment Create comparise		rdele referanse Klikk på Collat Klikk på Scree Klikk på Setup	oorate ning		
Name 944 Lien Nguyen	Coding Assignments       Id     Name       No records available.	Study Group	Codes to apply	Allocated	Started	Remaining	Collapse - Costss +
Ses applied from this set Rev ses Normal. Last code update: 20/05/2021 Cu	ewer 1 Reviewer 2 rrent User: Lien Nguyen Review:	(Reviewer 3) Lien test med Elisabet	(Only with this code)	Date	Quick Rep.	Details	Collapse Delete


Screening Distribute Work Create reference groups	Create new code Create coding assignment Create comparison	Fordele referanser
Setup Screening - Step 1: define what	to do	Klikk på Collaborate
This wizard will help you setting up "random" and 1. Screening tool and what to screen:	"priority" screening:	Klikk på Screening
2. How to screen: 3. Automation options		Klikk på Setup Wizard
	Not Configured 💌	Klikk på Codes
		screening (the active teaming system) works at the analysis charge to it might be some use for screening on full-Text, but is specifically designed to assist screening on title and abstract.
		You can restrict screening to "All items with this code", or screen all items available in the review. Most frequently, you'il screen all items.
	Previous Next Cancel	
Reviewers	Coding Assignments	Collapse
ID Name	Id 🗼 Name Study Group Codes to ap	ply Allocated Started Remaining
15944 Lien Nguyen	No records available.	
C		
Comparisons		

ew home References I	Frequencies Crosstabs Search	& Classify Collaborate Edit Tools With this Code 🔻 C	
reening Distribute Work Creat	te reference groups	Review Contains no Coding Tools	
Setup Screening - Step	1: define what to do	Klikk på Collaborate     Klikk på Collaborate	
	up "random" and "priority" screenin	□ Klikk på Screening	
Screening tool and what to How to screen:	screen:	□ Klikk på Setup Wizard	
. Automation options .1 Screeening Tool:	Not Configured 👻	□ Klikk på Codes	
in a concerning book	Hor configured	Klikk på den grønne knappen	
	ems) Items with this code: Previous	Vou can netricit screening to: "All forms with this code," or screen all items analable in the review. Most frequently, you'll screen all items:	2
eviewers	Coding Assignments	Collapse	
Name	Id Name Study Group	Codes to apply Allocated Started Remaining	
5944 Lien Nguyen	No records available.		
omparisons			

CININA Beta	Import Coding Tools		Lien Nguyen Logout
This wizard will help you set up the Codi	ng Tools in your review in just a few clicks.		Close/back
n EPPI-Reviewer Coding Tool (or Codesets) Coding Tools can be designed for all stages other coding needed. Coding Tools can are also be used to organ Coding Tools come in three types: Screenin	of templates or manually copy individual codesets into your review. are used to store most of the reviewing data so configuring your codesets correctly is of the review process. They are used as create screening (inclusion/exclusion) tools, d ise the review workflow and can be used to group together references according to or g, Administrative and Normal, the latter being used for data-extraction and similar tast s along with a description. Each template consists of a number of Coding Tools.	rdele referanser Klikk på Collaborate Klikk på Screening	ually any
Please pick One Option: Standard Review	Description: This template contai	Klikk på Setup Wizard	wo
Minimal Review	screening rounds, ar template is your bes	Klikk på Codes Klikk på den grønne knappen	doubt, this wanted
Manually pick from Public codesets Manually pick from your own codesets	ones and/or add mc Contains 6 Coding Tools.	Importer kodingsverktøyet	
	Cancel 2 Proceed +		
Status: Normal. Last code update: 20/05/20	221 Current User: Lien Nguyen Review: Lien test med Elisabet		

ew home References	Frequencies Crosstabs Search & Classify Colla	borate		Edit Tools With this Code *	
reening Distribute Work Cre	te reference groups Create new code Create coding assignme	nt Create comparison	Fo	rdele referanser	
Setup Screening - Step	1: define what to do			Klikk på Collaborate	
	up "random" and "priority" screening:			Klikk på Screening	
. How to screen:	o screen: Tool: Screen on Title & Abstract   All Items			Klikk på Setup Wizard	
. Automation options		This is the tool you will use to se		Klikk på Codes	
.1 Screeening Tool: 1	Screen on Title & Abstract 👻	Note that <b>priority screening</b> (t system) looks at title and abstra		Klikk på den grønne knappen	
		some use for screening on Full- designed to assist screening on		Importer kodingsverktøyet	
.2 What to sce 2	tems O Items with this code:	You can restrict screening to "Al code", or screen all items availa		Velg Screen on Title & Abstract > All	
<u> </u>	Previot 3 Next Cancel	frequently, you'll screen all item		Items > Klikk på Next	
eviewers	Coding Assignments			Collapse	
) Name	Id Name Study Group Codes to appl	y Allocated Started Rer	naining		
5944 Lien Nguyen	No records available.				
omparisons					
omparisons					


PPI International Beta eview home References Frequencies Crosstabs Search & Classify	Collaborate	Edit Tools With this Code 🔹 🕞 🖨
Screening] [Distribute Work] [Create reference groups] [Create new code] [Create coding a		Fordele referanser
Setup Screening - Step 2: define how to do it		Klikk på Collaborate
This wizard will help you setting up "random" and "priority" screening:		Klikk på Screening
1. Screening tool and what to screen: Tool: Screen on Title & Abstract   All Items 2. How to screen:		Klikk på Setup Wizard
3. Automation options		Klikk på Codes
2.1 Screening Mode: Priority	Use "Priority Screening" or randomise the c screened?	Klikk på den grønne knappen
	Note that it is <b>recommended</b> to enable Pri you have found a good number of both "Ir items (this is called Seeding).	Importer kodingsverktøyet
	Priority Screening will use a randomised lis will switch to priority mode when a <i>minima</i>	Velg Screen on Title & Abstract > All
	is available. Manual seeding is <b>recommended</b> because	ltems > Klikk på Next
	learn from better data. Thus, you may want "random" and then change to "Priority" on	Velg Priority
	representative sample of "Included" items also allows to evaluate how many "Includes overall (useful to decide when to stop scree	s" you expect to find
2.2 N. of people per item: One (Screening set is in "Normal" data entry mode). Click bare to enable changing its data entry mode. Previous Next	How many people should screen each item screening tool is in "Normal data entry" mo Otherwise. For doublon/multiple screening it is and can be risen to up to the number of me Please note that rising this number to more recommended (would make reconciliation) Cancel	ode: should be at least <b>two</b> , where members, et than three is <b>not</b>



3. Automation options	Use "Priority Screening" or rand		a andra la ublah lamar ana
2.1 Screening Mode:  Priority	screened? Note that it is <b>recommended</b> to you have found a good number	enable I	
	items (this is called <i>Seeding</i> ). Priority Screening will use a rand	omis F	Fordele referanser
	will switch to priority mode whe		Klikk på Collaborate
2.2 N. of people per item: One (Screening set is in "Normal" data entry	ius, you	may [	☐ Klikk på Screening
The selected screening tool is set for single coding (Normal Do you wish to change the data entry mode to Comparison	- Inclu	ded"	☐ Klikk på Setup Wizard
Change to Data Entry Mode: Comparison	when to	stop	□ Klikk på Codes
Train Are you sure you want to change to 'Comparison' data entry? This in Re		iles a	☐ Klikk på den grønne knappen
you will have multiple users coding the same item using this Coding then reconciling the disagreements. Please ensure you have read the			□ Importer kodingsverktøyet
check the implications of this.	and ch	ange [	□ Velg Screen on Title & Abstract > All
EXCI	type "l' mely i		Items > Klikk på Next
EXCL Yes, change to Comparison mode.	i not ir		❑ Velg Priority
EXCL			□ (1) Klikk på Repopulate (2) Tast inn
EXCLUDE on evidence [Exclude] [Change] [Delete]			<i>l've checked</i> (helt sant) (3) Klikk på
INCLUDE for second opinion Include Change Delete			rød firkant.
INCILIDE on title & abstract Include Change Todates		C	Klikk på Comparison
2.2 N. of people per item: One (Screening set is in 'Normal' data entry mode). Click here to enable changing its data entry mode.	How many people should screen screening tool is in "Normal dat Otherwise, for <i>double/multiple</i> s and can be risen to up to the nu Please note that rising this num		node. It should be at least two. review members.
	ukerveiledning v. 1.0 ©2	121	


2.1 Screening Mode: Priority ~	Use "Priority Screening" or randomise the screened? Note that it is <b>recommended</b> to enable	
	you have found a good number of both	
	items (this is called <i>Seeding</i> ). Priority Screening will use a randomis	Fordele referanser
3. Automation options	when a <i>m</i>	Klikk på Collaborate
3.1 Reconciliation Mode:	inded be	Klikk på Screening
Multiple (no auto-completion)	to "Priorit	
(Please select) Multiple (no auto-completion) yourself. Note that if man	ncluded" any people participate in screening, you many "In	Klikk på Setup Wizard
Multiple: auto complete (code level) Tr. Multiple: auto complete (include / exclude level)	en to stop achine to	Klikk på Codes
Multiple: auto complete (safety first) 3:2 Auto Exclude?	es titles a	Klikk på den grønne knappen
	ata that odes that	Importer kodingsverktøyet
EX	d change	Velg Screen on Title & Abstract > All
3.3 Indexing: EX The index is not up to date. This means that at the next training round the machine will re-in	index the titles and abstracts to ensure it in the index the titles and abstracts to ensure it in the index of the index o	Items > Klikk på Next
date data (training will take a little longer). FX If you believe that this is not necessary, click here.	at include	□ Vela Priority
EX in you domene that the necessary, then thereby		
EX		(1) Klikk på Repopulate (2) Tast inn
EX		<i>l've checked</i> (helt sant) (3) Klikk på
IN Previous Save settings Save and	d Create List Cancel	rød firkant.
INCLUDE on title & abstract [Include] Channel 2		Klikk på Comparison
2.2 N. of people per item: One (Screening set is in "Normal" data entry mode).	How many people should screen each its	





Review home References Frequencies Crosstabs	Search & Classify	Collaborate	
Review Items Import Items  Manage Duplicates Upda	te review		
	Deleted: 186	Duplicates: 109	
			Trene algoritme
Coding Progress Coding Tools 🔻 🗃			Klikk på Search & Classify
Screening Tools:			Your account expires on: 15. des. 2021 Current(shared) review expires on: 15. des. 2021.
🌋 Screen on Title & Abstract	<b>Ø</b> 31	• 0	Create Review
2 Screen on Full Text	15	• 0	
🤱 Screen T/A, Fear SR	<b>Ø</b> 317	• 0	
Standard Tools:			E
🤱 Risk Of Bias (Cochrane)	<b>Ø</b> 0	• 0	
2 Data Extraction	<b>O</b> 0	• 0	
1 NTRK	<b>Ø</b> 417	• 0	
Administration Tools:			
2 Allocations	<b>Ø</b> 0	• 0	
2 Retrieval status	<b>Ø</b> 0	• 0	

	rences Frequencies Crosstabs Search & Classify Collaborate			
ew Search Refresh	List Delete Selected Combine		REVIEW HOME	
∕	Name	Created By	Trene algoritme	
D 2	"Internet-based interventions for problem gamblers: self-directed recovery" (in Title and Abstract)	Lien Nguyen	Klikk på Search & Classify	*
0 1	Coded with: Usikker	Lien Nguyen	Klikk på New Search	



	bs Search & Classify Collaborate			
rresh List Delete Selected Combine  AND OR	Build Model Classify	Created By Lien Nguyen	REVIEW HOME Trene algoritme □ Klikk på Search & Classify	fier
NOT NOT (excluded)		Lien Nguyen	<ul> <li>[]</li> <li>Bruk eventuelt boolske symboler for å</li> </ul>	
Hjelp?				
(likk her 🖊 🖊				



### Machine learning classifiers – how to build your own in EPPI 4

#### What is a classifier?

Classification is the process of predicting data points. Classification predictive modelling is the task of predicting output variables from input variables. It belongs to the category of supervised learning where a human provides input data.

**For example:** Spam detection in email service providers can be identified as a classification problem. This is a binary classification since there are only 2 classes as spam and not spam. A classifier utilizes some training data to understand how given input variables relate to the class. In this case, known spam and non-spam emails have to be used as the training data. When the classifier is trained accurately, it can be used to detect an unknown email.

### When is this relevant for you?

You have already coded a set of references in a dichotomous manner (e.g. *includes/excludes* from screening or priority screening). Now you want to see if you progress is sufficient to apply machine learning to further references to save time with screening or to prioritise your efforts on more relevant studies. With a decent model, you can expect to get a ranking of your further references by % likely relevance. This will also allow you to allocate references by % likely relevance to team members, or set yourself a cut-off percentage of % likely relevance to stop screening.

**Note**: a decent model can be built if you have enough *include/exclude* screening decisions to train the model with. The more, the better. You have to build your model before assessing how useful it is; see "How to interpret the results from your model?" at the end of the document for more detail.

#### How to set up your classifier:

Before you get started you need a **training set** of known *includes /excludes* (e.g. your screening results). In addition, you need to create a code for all non-processed references to have them easily accessible.

#### 1. Codesets

Have your includes/ excludes ready. To get most sensible predictions of likely relevance, you need to have a balanced ratio of includes/excludes (ideally, not exceeding 1:5). You will be guided in how to balance your studies.


Codes	•
: 📭 🛈 C 🚍 🌱 💞	Ę
Screen on Title & Abstract	
INCLUDE	
🕞 🧸 🗾 Screen on Full Text	
▶ 🧸 🖊 Allocations	
🕨 🦾 📈 Retrieval status	
⊳ 🤱 🚰 Risk Of Bias (Cochrane)	


**Create** an **Administrative** codeset named: Reference for Classifier. Choose Codeset type: **Administrative**. It will then appear in blue.


"Add a child code" via right clicking on the Reference for Classifier. One for *Includes* and one for *Excludes* 

Check how many includes you have under "Screen on Title & Abstract". Right-click on Include and "list items with this code"

In the example there are 78 includes. Remember/ write down your number of *Includes*.







			rded.			
owin	g: [N	cιυ	DE			
I	ε	D				
_					Year	7
Go	E	1	Alshar Yalda ; Gr	Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People.	2020	
30	10	1	Andrea Dennis ;	Multi-organ impairment in low-risk individuals with long COVID	2020	
30	10	I	Arnold David T; I	Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort.	2020	
50	10	1	Betty Raman ; M	Nedium-term effects of SANS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital	2020	
20	10	I	Boscolo-Rizzo Pa	Evolution of Altered Sense of Smell or Taste in Patients With Nikly Symptomatic COVID-19.	2020	
30	10	1	Carfi Angelo ; Be	Persistent Symptoms in Patients After Acute COVID-19.	2020	
50	10	T	Carole H Sudre;	Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App	2020	
30	1	1	Caronna Edoarde	Headache: A striking prodramal and persistent symptom, predictive of COVID-19 clinical evolution.	2020	
50		I	Carvelho-Schneid	Follow-up of adults with noncritical COVID-19 two months after symptom onset.	2020	
50	E	1	Cellar Michole ; C	Characterization of Prolonged CEWID: 19 Symptoms in an Outpatient Telemodicine Clinic.	2020	
30	10	1	Chiesa-Estomba	Patterns of smoll recovery in 751 patients affected by the COVID-19 outbreak.	2020	
30	E	1	Daniel Ayoubkha	Epidemiology of post-COVID syndrome following hospitalisation with caronavirus: a retrospective cohort study	2021	
50	1	1	danilo buonsensc	Preliminary Evidence on Long COVID in children	2021	
30	E	1	Daryl Cheng ; Cl	Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis	2020	
io.	10	I.	Lizabeth Cirulii ;	Long term COVID-19 symptoms in a large unselected population	2020	
30	1	I	Garrigues Eve ; :	Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19.	2020	
30	10	T	Garrigues Eve ; :	Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19.	2020	
30		I	Goertz Yvonne M	Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?.	2020	
io.	1	I.	Guler Sabina A;	Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-1	2021	
50		I	Guler Sabina A;	Pulmonary function and ratiological features four months after COVID-19: first results from the national prospective observational Sviss COVID-1	2021	
in.	10	1	Halpin Stephen 1	Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation.	2021	
io i	8	1	Han X ; Fan Y ; /	Six-Month Follow-up Chest CT Endings after Severe COVID-19 Pneumonia	2021	
30	1	1	Hannah E Davis;	Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact	2020	
10	100	1	Honking C - Surr	Six month follow-up of self-reported loss of smell during the COVID-19 pandemic.	2020	

Select all references and assign them to childcode "Include" of the codeset Reference for Classifier.

You now need to assign a selection of your Excludes to childcode "Exclude" of the codeset Reference for Classifier.

Right-click on "Exclude", and then "list items with this code".

locarre	subs	See	nch Diagrams I	requencies Crosstata Reports Neta-analysis Collaborate My info Screening			Codes	
8 doos	rnert	s lo	ocked.				lime	
Shawin	g: TN	ci u	IDE					C - 4 %
Ι		D	490	P 38 995 499 1 A + 1			- 1 Z -	icreen on Title & Abstr LUDE
_	Ł	L	Autors 🛛 🖓	Tide	V	Year 🖓 *	INC	UDE
Go	V	r.	Atshor Yoldo ; G	Clinical Presentation of Caranavirus Disease 2010 (COVID-19) in Prognant and Recently Prognant People.		2020	+ 2 / 1	Inferences for Classific
Go	V	I.	Andrea Dennis ;	Nulti-organ impairment in low-risk individuals with long COVID		2020	- Excl	athe
Go	V	T.	Arnold David T; I	Patient outcomes after Inspitalisation with COVID-19 and implications for follow-up: results from a prospective UK othert.	Add child code		P.	
Go	7	1	Betty Raman ; M	Nedum-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and ment	List items with th			reen on hull lext
Go	V	I	Boscolo Rizzo Po	Evolution of Altered Sense of Smell or Taste in Patients With Hildly Symptomatic CDVID 19.	List items with th			locations
Go	V	I.	Carli Angelu ; Be	Pensistent Symptoms in Patients Alter Acute COVID-19.	List items without		en)	thricyal status
Co	V	T.	Garole H Sufrey	Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms St				sk Of Bias (Cochrane
Go	7	1	Caronna Edoardo	Headache: A striking prodromal and persistent symptom, predictive of COVED-19 clinical evolution.	List items without			one codeset
Go	V	r	Convolho Schnol	Follow up of adults with nonertical COVID-19 two months after symptom enset.	Display included		_	sta Extraction
Go	V	T	Gellai Michele ; C	Cheracterization of Prolonged COVID-19 Symptoms in an Outpatient Telemadicine Clinic.	Assign selected i			R code set title
Go	V	т	Chiesa-Estomba	Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak.	Remove selected	i items from the	s code	st covid model
Go		I.	Dariel Ayoubkha	Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study	Report: all text of	coded with this	code (all PDFs)	NG
Go	1	1	darilo buonsense	Preiminary Evidence on Long COVID in children	Delete code			st post covid
	-	-						ince nost could

		C 🔒 🌱 💞 Screen on Title & Abstract
	Add child code	UDE
atients with Cancer during the Pandemic	List items with this code	eferences for Classifier
	List items with this code (excluded)	de
	List items without this code	de
ervous System.	List items without this code (excluded)	creen on Full Text
30-year-old man.	Display included item frequencies (children)	llocations
	Assign selected items to this code	etrieval status
sicians During COVID-19 Pandemic.	Remove selected items from this code	isk Of Bias (Cochrane)
	Report: all text coded with this code (all PDFs)	core codeset
	Delete code	ata Extraction
		dit code set title
	Properties	ost covid model
li Arabia.	Сору	AG
	Paste	est post covid
·	2020	acore post covid

In the example there are 2171 references coded as "Exclude".

Documen	ts	Sear	ch Diagrams I	requencies Crosstabs Reports Meta-analysis Collaborate My info Screening
700 docur	men	ts lo	ded (out of 217	1 in this list in total).
Showing:	: EX	CLUE	E	
		_		
i I E		D	S 🖉 🕑 🐑	🕞 🔰 🕄 🕞 🖕 📥 🌾 🖃 🔲 🥵 🖶 Filter:
		-	Authors	Title
Go		I		AACR Calls on Congress to Take Immediate Action against COVID-19 and Protect Patients with Cancer during the Pandemic.
Go		I	Aakhus Eivind ; I	A prolonged course of COVID-19 in a person with dementia.
Go		I	Abate Giulia ; Me	Impact of COVID-19 on Alzheimer's Disease Risk: Viewpoint for Research Action.
Go		I	Abboud Hilal ; Al	COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System.
Go		I	Abdallah Hatem	Symptomatic relapse and long-term sequelae of COVID-19 in a previously healthy 30-year-old man.
Go		I	Abdayem Pamela	Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
Go		I	Abdelhafiz Ahme	Prevalence, Associated Factors, and Consequences of Burnout Among Egyptian Physicians During COVID-19 Pandemic.
Go		I	AbdelMassih Anti	The potential use of ABO blood group system for risk stratification of COVID-19.
Go		I	Abdel-Rahman N	To Fly Or Not To Fly? Aviation and Respiratory Diseases.
Go		I	Abdoli Amir ;	Iran, sanctions, and the COVID-19 crisis.
Go	=	T	Abe Toshikazu :	A patient infected with SARS-CoV-2 over 100 days.

To allocate a selection of "Exclude" not more than 1:5 of Include (i.e. 5 x 78 = 390), click the hand symbol to "Allocate items to codes randomly".

To not exceed the 1:5 ratio, calculate the correct amount percentage you need to assign.

In the example: (5 x 78) / (2171/100)= 17.97. So you need to allocate 17% in one group to the childcode "Exclude" of the codeset Reference for Classifier.

			V Yea	r V
ongress to Take Immediat	e Action against COVID-19 and Protect F	Patients with Cancer during the Pandemic.	202	0
D-19 on Alzheimer's Disea	se Risk: Viewpoint for Research Action.		202	0
lapse and long-term sequ	elae of COVID-19 in a previously healthy	30-year-old man.	202	0
e of ABO blood group syst	em for risk stratification of COVID-19.		202	0
and the COVID-19 crisis.	Allocate items to codes randomly	x	202	0
Adverse Pregnancy Outcon		All with this code	202	0
e tissue, inflammatory bi		All with this code •	202	10
pact of COVID-19 pander		EXCLUDE 🔻 hiopia.	202	10
ves Could Be Saved In Th	Create codes below this code / set	Exclude	202	0
e impact of COVID-19 pan			202	0
sions and pneumothorax i	Percentage to allocate	17 🗧	202	1
e and perinatal care in the	Number of groups to create	1	202	0
iabetes: A Narrative Revie		Included items     Excluded items	202	10
ndon, a Case Series Demo	1		202	10
isis as a career shock: Im		Go!	202	0
ristics and short term out	comes after recovery from COVID-19 in	patients with and without diabetes in Bangladesh.	202	0
droxychloroquine as a trea	atment of COVID-19.		202	0
tatus anadista mastalitu in	a cohort of 138 hospitalized patients wit	1 00100 10	202	


Under the codeset Reference for Classifier/ Exclude you find "Group 1" – your random selection of excludes.

Your references which haven't been screened need to have their own code too. For example, you can code them to a code "need to be screened" under the allocations codeset.


To find the not screened studies, go to the search tab, and search for studies "that don't have any codes from this set" "Screen on Title & Abstract". Assign these studies to your "Need to be screened" code.

1.a) Create an Administrative codeset named: Score codeset

1. b) Check that your: Score codeset is visible and blue










👬 / Score codeset

▶




**1. c)** "Add a child code" via right clicking on the score codeset


**1. d)** Name the childe code: Number and date it, and provide the information on how many includes/excludes you have ready



### 2. The Classifier menu

**Click** on the spanner "classifier" icon to get the Machine building classifier menu






# The Machine building classifier menu


#### 3. Build the model

Apply the **Reference for Classifier: Include** code from **Reference for Classifier/ Exclude/ Group 1** code.



Name the model "Classifier INCLUDE vs EXCLUDE, [number of include – number of exclude]"

*Example*: "Classifier INCLUDE vs EXCLUDE, 50-200" shows that this model has been trained by 50 included studies and 200 excluded studies.



Build the model Lea (Wait a few minutes.)	Stage 1: build the model	age 1: build the model							
Build the model	Learn to apply this code	INCLUDE							
(Mait a faur minutas)	Distinguish from this code	EXCLUDE 🔻							
(wait a few minutes.)	Name for your model	Edit title							
		🥟 Build model							
	(Go straight to stage 2 if you are applying one of t	he 'pre-built' models.)							

## Your **model is ready** based on your *includes* and *exludes*!

### 4. Apply the model

Go to Stage 2 (right side): Applying the model to uncoded/not screened studies

lachine learning classifiers							- 0
the code by building a model (which is saved for f Three 'pre-built' classifiers are available, which ca 'DARE' database; and 9,000 records in CRD's NHS	future use); and then the model is applied to new its in automatically identify RCT, systematic reviews, an	d economic evaluations. They have been built from: 26 views and Dissemination (CRD) at the University of Yor	30,000 records scr	eened by Cochran			
Stage 1: build the model		Stage 7: apply the model			C R	efresh model li	st 👂
Learn to apply this cade	INCLUDE *	Tirlo 🖓	Applies 🛛 🕅	Compared wi 🏹	Precision 😵	Recall 🛛 😵	
Natinguish from this code	EXCLUDE *	Mediine model	INCLUDE	EXCLUDE	0.09	0.80	Rebuild
larme for your model	Fuil Obe	WHO search (after PS 100)	INCLUDE	EXCLUDE	0.57	0.57	Rebuild
		WIIO search (after PS 140)	INCLUDE	EXCLUDE	1.00	0.50	Rebuild
		WHO search (after 198)	INCLUDE	EXCLUDE	0.80	1.00	Rebuild
	🕸 Baild model	Nodel for NNS	INCLUDE	EXCLUDE	0.80	0.89	Rebuild
		<ul> <li>Apply above selected model</li> </ul>	• Apple	to all items in rev	view		
		C Apply Cochrane RCI Classifier	O Apply	to items with the	s code		
		<ul> <li>Apply systematic review model</li> </ul>					
		Apply economic evaluation model	O Apply	to items from the	s source		
		C Apply original RCT model					
					🎭 Apply	model	
Normal Last role undate: 15/82/2021 Lisee: 1	ton Hannels I Beserve ML test environ		_		_	_	

Stage 2: apply the model		C Refresh model list						
Title	V	Applies 🛛 🏹	Compared wi 🏹	Precision 🍸	Recall 🛛 🏹			
Test model		INCLUDE	EXCLUDE	0.09	0.80	Rebuild		

**4.a) Select** the model you just built

**4.b) Select** the studies to apply the model to:

specific code (that describes your un-processed studies, i.e. "need to be screened" (the code specified in point 1) **or** a specific source (i.e. a RIS-file)

Stage 2: apply the model					C R	efresh m	oael li	st 👂
Title	V	Applies	V	Compared wi 🏹	Precision 🟹	Recall	V	
Test model		INCLUDE		EXCLUDE	0.50	0.60		Rebuild
Apply above selected model     Apply Cochrane RCT Classifier     Apply systematic review model				to all items in rev to items with this Need to				
<ul> <li>Apply economic evaluation model</li> </ul>		A	pply	to items from this	s source			
Apply original RCT model								Ŧ
					👒 Apply	model		

#### Now: Apply model

Stage 2: apply the model			C Refresh model I						
Title	V	Applies 🛛 🕅	Compared wi 🏹	Precision 7	Recall 🛛 🖓				
Test model	INCLUDE EXCLUDE 0.50 0.60 Rebuild								
Apply above selected model     Apply Cochrane RCT Classifier			y to all items in rev y to items with this						
O Apply systematic review model		Need to be screened							
O Apply economic evaluation model	O Apply to items from this source								
Apply original RCT model						*			

#### Wait for a few minutes.

# 5. Find the results of your model

Choose the "Search" tab to see the results.

You will likely have to click "Refresh search list" a few times

By clicking "Visualise", you get a distribution chart. By clicking on "Select", you get a list of the references with ranking by relevance.


You want to **visualise** your results

After clicking "Visualise", a distribution chart **pops up** 

In the example to the right, about 120 studies are ranked as 20-29% likely included; only a few are ranked as 0-9% likely.

Jocu	iments	Search Diagrams Frequencies Crosstabs Reports Meta-ar	alysis Collaborat	e My info	Screening	
<u>an</u>	New	search 🛭 😨 Refresh search list 🎇 Delete selected 🛛 🧭 Combine	e 💿 AND 🕥 O	r 🔘 NOT I	included) 🤇	🕥 NOT (excluded
	7	Title	Created by	Date 🛛	Hits 🏹	List
	39	Items classified according to model: Test Model	Jan Himmels	05.02.2021	320	Select Visualise
	38	Not coded with: Screen on Title & Abstract	Jan Himmels	05.02.2021	320	Select
	37	34 AND 33	Jan Himmels	05.02.2021	884	Select
	36	35 AND 33	Jan Himmels	05.02.2021	320	Select
	35	Not coded with: WHO not screened	Jan Himmels	05.02.2021	1397	Select
	34	Coded with: WHO not screened	Jan Himmels	05.02.2021	1065	Select
	33	Not coded with: Screen on Title & Abstract	Jan Himmels	05.02.2021	1204	Select


)ocu	ments	Search Diagrams Frequencies Crosstabs Reports Meta-ar	alysis Collaborat	e My info	Screening	
de la compañía de la comp	New	search 😨 Refresh search list 💥 Delete selected 📎 Combine	🛛 🔘 AND 🕥 O	r 🔘 NOT (	included) 🤇	NOT (excluded
	٦	Title V	Created by	Date 🏹	Hits 🏹	List
	39	Items classified according to model: Test Model	Jan Himmels	05.02.2021	320	Select Visualise
	38	Not coded with: Screen on Title & Abstract	Jan Himmels	05.02.2021	320	Select
	37	34 AND 33	Jan Himmels	05.02.2021	884	Select
	36	35 AND 33	Jan Himmels	05.02.2021	320	Select
	35	Not coded with: WHO not screened	Jan Himmels	05.02.2021	1397	Select
	34	Coded with: WHO not screened	Jan Himmels	05.02.2021	1065	Select
	33	Not coded with: Screen on Title & Abstract	Jan Himmels	05.02.2021	1204	Select




## 6. Saving your results as codes by % likely relevance

Select the child code under the "Score codeset" to save each bar as a code (the child code you created in Step 1.d).


Click "Create!"



Under your administrative Score codeset, and under the **child code** you can find each bar from the chart, as its own code.



Consider your options:	With your results ready, you need to assess their usefulness, if you are satisfied with the results you may want to code studies with low/high likely relevance as includes or excludes, or you can allocate them to a member of your team so screen them.
Interpret your results	
A decent model Your results, visualised in the bar chart, reflect the strength of the model. The example below shows a distribution with few studies having a high % likely relevance, and gradually more with less likely relevance. The example reflects a rather good model, with the most relevant studies already having been identified.	A model that needs to be trained more or adjusted The results of a less successful model are depicted below. The model was not able to be very certain in which studies were most likely relevant, or which studies were unlikely relevant. This indicates that the classifier had too little data available to make more certain predictions.
In this case you can continue on to changing your screening procedures.	In this case, you should continue screening, and rebuild the model once you have screened more studies (rule of thumb: 50-100 studies).
Distribution of classifier scores - Model: Model for NNS	Distribution of classifier scores - Model: Medline model




 Create! Create codes below this code / set 700 600 8 500 400 300 200 100 40-49 5 Range 0-9 10-19 20-29 30-39 50-59 60-69 70-79 80-89 90-99 ing • more than ) less than between 50 \* Save Close


If after you continue screening your model is still clustered around 50-60%, try making your *includes* and *excludes* more balanced. This likely means picking a new, smaller random selection of *excludes*.

#### Changing your screening procedures based on your classifier


If you have built a decent classifier, you have several options. Some examples:



One person, instead of two, can confirm the studies classified as very likely (90-99%) and as very unlikely (0-9%).



Without manual confirmation, you can screen the studies classified as very likely (90-99%) and as very unlikely (0-9%) according to the classifier's prediction.



One person, instead of two, can confirm the studies classified as less

likely (0-29%).

Or other combinations.

You could also de-prioritize the screening of least likely studies, so that the team proceeds with other tasks, and these least-likely studies are screened whenever people have time.

## 8. a) How to accept the classifier's screening predictions

If you want to accept the classifier's prediction of a screening code (without a human screener), you must still be the one to actually assign a code.

You can do this by searching and coding in bulk. E.g. you decide to exclude all studies with less than 10% likely relevance.

Open the search tab and create a new search.

Documents	Search Diagram	s Frequencies	Crosstabs	Reports	Meta-analysis	Collaborate	My info	Screenin				
🗿 New s	search 😨 Refresh	search list 🎽	Delete sele	ected 📎	Combine 🔘	AND 🔘 OR	O NOT	(included				
7	Title											
49	Coded with: 0-9%	range										
<b>4</b> 8	47 AND 46											
<b>4</b> 7	Coded with: INCLU	DE										
<b>4</b> 6	42 OR 41 OR 40 O	R 43 OR 44 OR	45									
<b>4</b> 5	Coded with: 30-39	oded with: 30-39% range										
<b>4</b> 4	Coded with: 40-49	% range										
43	Coded with: 50-59	% range										

Search for the % range you want to assign the include/ exclude code to (e.g. 0-9% range)

	Jan Himmels 15.02.2021 4	Selec
Search		Selec
Find documents	with this code 👻	Sele
	0-9% range	Sele
	o s winninge	Sele
	Screen on Title & Abstract	Sele
	Screen on Full Text	Sele
	Allocations	
	Retrieval status	Sele
	Risk Of Bias (Cochrane)	Sele
	204	Sele
	▲ Score codeset 84	Sele
	▲ Classifier 1, date (includes/excludes)	
	0-9% range 81	Sele
	10-19% range 4	Sele
	20-29% range 248	Sele
	30-39% range 0	Sele

Select the search result via the checkbox

In the Codes menu on the right side, right-click on "EXCLUDE", then click "Assign items in selected searches to this code."

**NB!** If your **Screening on T/A codeset** is set up to require two persons' coding ("Comparison coding"), and you want to keep this set-up rather than change to allow single-person coding ("Normal coding"), then a second person needs to screen these studies. Allocate this same range to a second person with instruction to bulk-screen them as you did, then make a comparison as you normally would to confirm screening.

#### 8. b) How to allocate studies by likely relevance

Doc	uments	Search Diagrams Frequencies Crosstabs Reports	te My Info	Screening		Codes
i d		search 🕐 Refresh search list 💥 Delete selected 🔗	OR 🔘 NOT (	included)	ļ	i 🖪 🕤 C 🗏 🔍 🔗
	7	Title	Date 💎	Hits 🛛 🖓	List 📩	
~	49	Coded with: 0-9% range	16.03.2021	3	Select	🔺 🤱 🗾 Screen on Title & Abstract
	48	47 AND 46	15.02.2021	14	Select	- EXCLUDE
	47	Coded with: INCLUDE	15.02.2021	78	Select	Add child code
	46	42 OR 41 OR 40 OR 43 OR 44 OR 45	15.02.2021	118	Select	List items with this code
	45	Coded with: 30-39% range	15.02.2021	58	Select	
	44	Coded with: 40-49% range	15.02.2021	40	Select	List items with this code (excluded)
	43	Coded with: 50-59% range	15.02.2021	13	Select	List items without this code
	42	Coded with: 60-69% range	15.02.2021	4	Select	List items without this code (excluded
	41	Coded with: 70-79% range	15.02.2021	2	Select	Display included item frequencies (chi
m	40	Coded with: 80-89% range	15.02.2021	1	Select	Assign items in selected searches to the

If you want certain team members to prioritize screening of certain studies based on likely relevance, you can create specific allocations in the **"Collaborate"** tab. 

 CPP\* Ruters 324112
 Image: Comparison of Comparison of

Click "Create new"

i. Select the range you want to allocate.

**ii.** Select the codeset you want the individual to code

iii. Select the person to allocate to

iv. Assign the work.

The person to whom you allocated to will see the
assigned references, in the " <b>My info</b> " tab, and
there under "My work allocations".

1	Assign work				23	hew
	Code stud	ies in this group (i. that have this cod		0-9% range	•	
		Using this code s	et	Screen on Title & Abstract	•	
		To this perso	on	Jan Himmels	•	
_	As	sign work	1	Cancel		


Docume	ents	Search	Diagrams	Frequencies	Crosstabs	Report	s Me	ta-analysis	Collabora	ite My info	Screenin	g	
						t (share		on 15.12.20 iew expires o				New	review
Select	Revi	ew				V	id 🏹	Last Logon	7	New items	8	Owner	V
Go	Covi	d-19 livi	ng review				21865	2/12/2021	1:17:38	0		Ley Muller	
Go	EUnetHTA RCR						26223	1/26/2021	9:29:26	0		Stijn Van de Vel	
Go	Jan Himmels's example non-shareable review						25781	12/10/202	0 3:20:31	0		Jan Himmels	
Go	Jan Himmels's example non-shareable review					25782	12/10/202	0 3:18:45	0		Jan Himmels		
Go	ML t	est proje	ect				21866	3/16/2021	1:50:25	333		Jan Himmels	
Go	Test	MAG					25168	3/16/2021	11:26:06	26		Ley Muller	
My wo		ocations:	:					Group of stu	ulias		Allocated	Charled	Bama
							_						Remai
Screen	n on T	itle & Ab	stract					0-9% range			3	0	

# Risk of Bias assessments with machine learning

In EPPI-Reviewer

Instructions for team leaders







Technology

• <u>www.robotreviewer.net</u>

## Before you begin RoB assessments

- Request Silverlight access from NHN for you and your team (as early as possible)
- Set your team up in EPPI
- Call in Ley/someone from the machine learning team to talk through possible procedures, such as:
  - Should your team members be blinded to RobotReviewer?
  - Do you want to compare to not using machine learning?
  - Can we collect some data?
- Set up a 1-hour training meeting with your team and Ley, to explain procedures
- Recommended: another 1-hour meeting with your team and Ley, for them to begin assessments







### 3. Change RobotReviewer codeset to «comparison» type

so that each researcher's asessments are tracked but not immediately visible to others

Right click on codeset  $\rightarrow$  Properties







RobotReviewer only completes the first 4 domains, so you need to add the rest.

# 4. Add remaining 3 domains to the *Risk of bias (on full document)* codeset.


Right click on this code  $\rightarrow$  Add child code.




This is how your 3 new domains should look:



# Add Cochrane's instructions to each code description:





6. Allocate to your team members as appropriate, making it clear who is the primary researcher who fills out the entire form and who is checking their work.

Send them the instructions for team members document.

Schedule a 1.5-2 hours meeting with your team <u>and</u> someone from the machine learning team, to train and begin assessing together.

# Risk of Bias assessments with machine learning

In EPPI-Reviewer

#### Instructions for team members


## Technology

• <u>www.robotreviewer.net</u> (drag and drop a pdf of an RCT to see whathappens)

• EPPI Reviewer has RR's technology built it, so researchers can skip the website.

 RR completes the first 4 of 7 domains in Cochrane's Risk of Bias. Developers suggest using RR as a support, not as an independent researcher.

• What is potentially even more helpful, is that it provides the text it used to make each judgement. That text by itself can be used by researchers.



**CPPI** Beta Feedback Help Ley Muller Logout Review home References Frequencies Crosstabs Search & Classify Collaborate • Web version in Chrome, Review Items Import Items 
Manage Duplicates My Reviews My Work 1 iources 4 Firefox, Edge, Safari Included: 31 Excluded: 7143 Deleted: 0 Duplicates: 0 https://eppi.ioe.ac.uk/ep Codes to apply Grour pireviewer-web/ Coding Progress Coding Tools RobotReviewer in EPPI: Line classifications #1. Marie #2 • Find your assignment Asstract 6778 0 396 Screen on Full Text 0 73 02 Standard Tools: Are you using version 4? & Risk Of Bias (Cochrane) 00 00 Skip to those 2 Data Extraction 80 00 Your account expires on: 12/15/2020 instructions Current(shared) review expires on 12/15/2020. A Data Extraction 00 00 Create Review 00 A A& 20 he RobotReviewer classifications 01 • 15

٠

## How has your project leader told you to assess RoB?

- Blinded to your other team members (but not blinded to machine learning)
  - Use slides 5-9
- Not blinded to your other team members
  - Use slides 10-12

## Blinded to your team members

CINY Beta	Item Details	Feedback [Hep] Ley Muller Logo
+ • • /	First Previous Next Last Itom 1 of 3	Show terms?  Auto Advance?  Close/
Construction on Title & Abstract	Item Details Arms and Timepoints PDF Coding Record	
A      Z      Included      A      Z      Z Screen on Full Text	Ref. Type: Journal, Article	🖉 Find on: 🔹 Show optional fields? 😑 🐖 💽
Allocations	Effect of Inpatient Multicomponent Occupational Rehabilit	
🔹 🚊 🕗 Retrieval status	Outpatient Rehabilitation on Sickness Absence in Persons v	with Musculoskeletal- or Mental Health
🔹 🤱 😋 🤹 Risk Of Bias (Cochrane)	Disorders: A Randomized Clinical Trial	
2 Oata Extraction	Abstract:	
A O Z Data Extraction	Purpose To assess effects of an inpatient multicomponent occupational rehabilitation prog	
2 O / A&L	sickness absence in persons with musculoskeletal- or mental health disorders. Methods Ra individuals 18-60 years old on sick-leave for 2-12 months with a sick-leave diagnosis within	
RobotReviewer classifications	chapters of ICPC-2, identified in a national register. The inpatient program (4 + 4 days) con	
<ul> <li>Risk of bias (on full document)</li> </ul>	training and work-related problem-solving including creating a return to work plan and a	
<ul> <li>PICO text (full text)</li> </ul>	consisted primarily of ACT (6 sessions during 6 weeks). Both programs were group based.	
<ul> <li>Sample size</li> </ul>	at 6 and 12 months follow-up. Secondary outcome was time until sustainable return to wo program (n = 92) or the outpatient program (n = 76). We found no statistically significant of	
<ul> <li>Punchline</li> </ul>	absence days at 6 and 12 months follow-up. In the outpatient program 57% of the particip	
<ul> <li>MeSH Terms</li> </ul>	in the inpatient program 49% (log rank, p = 0.167). The hazard ratio for sustainable return	
<ul> <li>Study type classifiers</li> </ul>	outpatient program. Conclusions This study provided no support that the more compreher	
<ul> <li>PICO Spans (from abstract)</li> </ul>	rehabilitation program reduced sickness absence compared to the outpatient rehabilitation	
<ul> <li>Risk of bias (on abstract alone)</li> </ul>	Author(s) Aasdahl L ; Pape K ; Vasseljen O ; Johnsen R ; Gismervik S ; Halsteinli V ; Flete	en N ; Nielsen C V; Fimland M S;
	Journal Journal of Occupational Pahabilitation	

 First, download the pdf and move it to a different window

Freated by: He	id Nøkleby	Created on: 5/15/2020	Diseases/px [Psych Edited by: Line Holtet Evensen	Edited on: 12/9/2020	
	srettede tiltak	sr prim (1).txt			
Upload					
Docume	nts:				
Id	Ref	File Name		Actions	
501768	Aasdahl (2018)	Aasdahl 2018 .Effect of Inpatient Multicompone Rehabilitation pdf.pdf	nt Occupational Rehabilitation Versus Less Comprehensive	Outpatient	0

5

## Option 1: Blinded to your team members

 Codeset you are interested in: RobotReviewer classifications

	Item Details	[Feedback][Herp] Ley Muller Logou
+ • • /	First Previous Next Last Item 1 of 3	Show terms?  Auto Advance?  Close/b
Ag ⊘ / Screen on Title & Abstract Ag ⊘ / Included Ag ⊘ / Screen on Full Text Ag ⊘ / Reference Issues Ag ⊘ / Reference Issues Ag ⊘ Arsk Of Bias (Cochrane)	Item Details Arms and Timepoints PDF Coding Record  The Type: Journal, Article  Effect of Inpatient Multicomponent Occupational Rehabl Outpatient Rehabilitation on Sickness Absence in Person Disorders: A Randomized Clinical Trial	
	Abstract Puppose to assess effects of an inpatient multicomponent occupational rehabilitation p sickness absence in persons with murculoskeletal- or mental health disorders. Method individual 19-60 years old on sick-keeve for 2-12 months with a sick-keeve diagnosis w chapters of CR-2; dentified in a national register. The inpatient program (4 + 4 days) training and work-related problem-solving including creating a return to work plan and consisted primnity of ACT (8 sessions during of weeks). Both programs were group bases at 6 and 12 months follow-up. Secondary outcome was time until sustainable return to program (n = 52) or the outpatient program (n = 76). We found no tastiscially signifi- absence days at 6 and 12 months follow-up. In the outpatient program 57% of the part in the ingratent program 45% log arek, p = 0.167. The heard ratio for sustainable eret outpatient program 45% log arek, p = 0.167. The heard ratio for sustainable eret outpatient program 45% log arek, p = 0.167. The heard ratio to sustainable eret outpatient program 45% log arek, p = 0.167. The heard ratio to routpatient rehabilitation program for each situation significant absence compared to the to tradition program 45% log arek, p = 0.167. The heard ratio for sustainable eret outpatient program 45% log arek, p = 0.167. The heard ratio for sustainable eret outpatient program 45% log arek, p = 0.167. The heard ratio constaincing legisling the significant program 45% log arek p = 0.167. The heard ratio to sustainable eret outpatient program 45% log arek p = 0.167. The heard ratio to sustainable eret outpatient program 45% log arek p = 0.167. The heard ratio to sustainable eret absence days at 6 and 12 months follow-up in the upper the heard or the the more compared to the heard since absence compared to the outpatient rehability of the parts rehability of th	8 Randomized chical that with parallel groups. Participants were thin the musculoselextal, psychological or general and unspecified consisted of Acceptance and Commitment Therapy (ACT), physical d a workplace visit (Crossidered relevant. The outpatient program ed. Primary outcome was cumulated number of sickness absence days work. Results 16 Biodividuals were analomized to the inpatient and difference between the programs in median number of sickness itogants achieves dustainable return to work (median time of montha), um to work was 0.74 (39% CI 0.48-132, p = 0.16%), in favor of the ensiste 4 + 4 days inpatient millicomponent occupational
· rico opena (nom absuaco	Author(s) Aasdahl L ; Pape K ; Vasseljen O ; Johnsen R ; Gismervik S ; Halsteinli V ; F	

#### Option 1: Blinded to your team members

> Punchline MeSH Terms Study type classifiers PICO Spans (from abstract) Risk of bias (on abstract alone)

- Turn on live comparisons to see machine learning assessments (this breaks blinding):
- Coding record  $\rightarrow$  View the person whose codes represent machine learning (your project leader will tell you).

CEPPI EXVIENCE Beta				Item Details			
+ • •	First	Previous Next	Last Item 1 of	3			Show terr
🕨 Ale 🖉 🖉 Screen on Title & Abstract	Live	Comparison					
Included	No c	oding to compare/s	how. Please select a	ny code (or coding tool) on the left	if coding is present for ch	ildren of the s	elected code/too
🕨 🏖 🗢 🗹 Screen on Full Text	Item	Details Arms an	d Timepoints	PDF Coding Record			
Allocations	_						
Retrieval status			mparison				
🕨 🤱 🖨 😭 Risk Of Bias (Cochrane)		ing Tool 1		Reviewer Heid Nøkleby	Completed	Locked?	View 🗈
🔒 😑 🗡 Data Extraction				Lev Muller	0	NO	View D
A Contraction		ootReviewer classifications		Line Holtet Evensen	0	No	View D
1 O 🗸 A&L		otReviewer classifications		Maria Bierk		No	View D
<ul> <li>A Construction</li> <li>A Robot Reviewer classifications</li> </ul>		ootReviewer classifications		Alexander Tingulstad	•	No	View 10
<ul> <li>Risk of bias (on full document)</li> </ul>	Scr	een on Title & Abstract		Melanie Ames	•	No	View 🗈
<ul> <li>PICO text (full text)</li> </ul>	Scr	een on Title & Abstract		Heid Nøkleby	0	No	View 🗈
<ul> <li>Sample size</li> </ul>							

7

#### Option 1: Blinded to your team members

#### Aasdahl (2018) [ID: 47249610]

#### Reviewer: Alexander Tingulstad

#### RobotReviewer classifications (incomplete)

#### Risk of bias (on full document)

- · Random sequence generation Low
  - Between October 2012 and November 2014,

12 007 potential participants from the regional area were identiied in the National S program. A lexibly weighted randomization procedure was provided by the Unit of Aj Sickness absence data was registered and provided by employees at the Norwegian V · Allocation concealment

Low

Sickness absence data was registered and provided by

employees at the Norwegian Welfare and Labor Service whom were unaware of grou Between October 2012 and November 2014, 12 007 potential participants from the r randomized to receive an invitation to the short program.

- Blinding of participants and personnel High / unclear

It was not possible to blind neither the participants nor the caregivers for treatment. This afected group-sizes differentially, and therefore the researchers were or the outpatient program.

- Blinding of outcome assessment
  - High / unclear

This afected group-sizes differentially, and therefore the researchers were not blinded It was not possible to blind neither the participants nor the caregivers for treatment. and during (monthly) the intervention.

#### • PICO text (full text) • Population


Eliaible participants were 18 to 60 vears of aae sick

- A new window will pop up displaying the automated risk of bias assessments.
- Any text extracted will be in italics

Option 1: Blinded to your team members

# Your assignments

- 1. Fill out all 7 domains in *Risk of bias (on full document)* 
  - a) Check the correct code (Low or High/unclear)
  - b) Click on Info and add in support for your assessment. Copy the text extracted by machine learning, if you agree, otherwise copy from the pdf, or write in your own text. Specify «high» vs «unclear» in the info box.



9

## Option 2: Not blinded to your team members

- Codeset you are interested in: RobotReviewer classifications
- Open pdf: Download

+	First Previous Next Last Item 1 of 3	Show terms?  C Auto Advance?  Close/ba
An O Screen on Title & Abstract A O ∠Included An O ∠Screen on Full Text A O ∠Allocations	Item Details Arms and Timepoints PDF Coding Record Tem Total Arms and T	
A O Retrieval status A O Risk Of Bias (Cochrane)	Outpatient Rehabilitation on Sickness Absence in Per Disorders: A Randomized Clinical Trial	rsons with Musculoskeletal- or Mental Health
	Astract: Purpose To assess effects of an inpatient multicomponent occupational rehabilitat sickness absence in persons with muculoskeletal- or mental health disorders. Me individuals 16-60 years of on sick-lever 60-21 cumonits with sick-lever diagno- chapters of ICPC-2, identified in a national register. The inpatient program (4 + 4 training and work-related problem-solving including creating a return to work pla- consisted primarily of ACT (6 sessions during 6 weeks). Both programs were group at 6 and 12 months follow-up, Secondary outcome was time until sizuitabile retur- program (n = 92) or the outpatient program (n = 76). We found no statistically gis absence days at 6 and 12 months follow-up, In the outpatient program 5% of the in the impatient program 4% log rank $\mu$ = 0.167. The hazard ratio for sustainabil outpatient program. Conclusions This study provided no support that the more co- rehabilitation program reduce diskness absence compared to the outpatient program for approximation of the size of the	ethods Randomized clinical trial with parallel groups. Participants were oois within the musculoskeletal, psychological or general and unspecified days) consisted of Acceptance and Commitment Therapy (ACT), physical an and a workplace visit if considered relevant. The outpatient program p back-Pinnary outcome was cumulated number of sickness absence days un to work, Results 168 individuals were randomized to the inpatient opficient difference between the programs in median number of sickness e participants achieved sustainable return to work (median time 7 months), lie return to work was 0.74 (95% Cl 0.44-1.32, p = 0.165), in favor of the omprehensive 4 + 4 days inpatient multicomponent occupational
	Author(s) Aasdahl L ; Pape K ; Vasseljen O ; Johnsen R ; Gismervik S ; Halsteinli	li V ; Fleten N ; Nielsen C V; Fimland M S;

reated by: He		Created on: 5/15/2020	Edited by: Line Holtet Evensen	Diseases/px [Psychology] *Musculoskeletal Diseases/rh Edited by: Line Holtet Evensen Edited on: 12/9/2020				
_	ırettede tiltak sr pr	im (1).txt	Duplicate IDs:					
Upload Docume	nts:							
Id	Ref	File Name			Actions			
501768		Aasdahl 2018 .Effect of Inpatient Multicomponen Rehabilitation pdf.pdf	t Occupational Rehabilitation Versus Less Comprehensive	e Outpatient	Download			

Option 2: Not blinded to your team members

MeSH Terms

Study type classifiers

 PICO Spans (from abstract) Risk of bias (on abstract alone)

- Turn on live comparisons to see machine learning assessments (this breaks blinding):
- Coding record  $\rightarrow$  Live comparison  $\rightarrow$  Citation details  $\rightarrow$  click on the specific code you want to see. The child-codes immediate subordinate will be shown, so you might have to use the arrows to expand a code.

		Item Deta	ils	
+ • •	F	irst Previous Next Last Item 1 of 3		Show terr
<ul> <li>▶ 2 Screen on Title &amp; Abstract</li> <li>▶ 2 ⊘ Included</li> </ul>		ive Comparison Io coding to compare/show. Please select any code (or coding to	coll on the left: if coding is present for children of the sele	cted code/toc
<ul> <li>▶ ♣ ○ Z Screen on Full Text</li> <li>▶ ♣ ○ Z Allocations</li> </ul>	Æ		Record	
Retrieval status	Ľ	un Comparison 🖺 Live Comparison 🕰		
Risk Of Bias (Cochrane)		Coding Tool	Reviewer	Complete
🔒 🗢 🔀 Data Extraction		Allocations	Heid Nøkleby	0
A      Z     Data Extraction		Included	Ley Muller	0
RobotReviewer classifications	0	RobotReviewer classifications	Alexander Tingulstad	•
Risk of bias (on full document)		Screen on Title & Abstract	Melanie Ames	•
PICO text (full text)     Sample size		Screen on Title & Abstract	Heid Nøkleby	0
Punchline				

11

#### Option 2: Not blinded to your team members


- Take a look at the information ٠ already available.
- The code relevant to you is Risk of bias (on full document), while this can be helpful: PICO text (fulltext). But the others also have interesting info.
- NB! You won't see any coding on ٠ the left side, because the assessment isn't completed yet. Look at the top of the screen for RR's coding, which will be marked under your team leader's name (or someone else on the machine learning team).
- Any text extracted will be ٠ displayed after [Info]

	Item Details	
+ * * /	Tist Frevious Next Last New1978	Show terms?
a 🖉 🗡 Screen on Title & Abstract	Live Comparison	
2 O / Included	Alexander Tingulstad 🖨	
la 🗢 🖌 Screen on Full Text	- Low	
Allocations	[Info] Between October 2012 and November 2014, 12 007 potential participants from the regional area were to receive an invitation to the short program. A lexibly weighted randomization procedure was provided by the short program.	
	Occup Rehabil (2018) Sickness absence data was registered and provided by employees at the Norwegian We	
🤱 😑 🔀 Retrieval status	Item Details Arms and Timepoints PDF Coding Record	
🤱 😑 🚖 Risk Of Bias (Cochrane)	Tem berails Anns and timebolitis PDP Coolind Record	
🖁 😑 🗡 Data Extraction	Ref. Type: Journal, Article	🖉 Fin
🤱 🖨 🔀 Data Extraction		
🔒 😑 📈 A&L	Effect of Inpatient Multicomponent Occupational Rehab	
№ 😄 🗡 RobotReviewer classifications	Outpatient Rehabilitation on Sickness Absence in Person	s with Musculoskeleta
<ul> <li>Risk of bias (on full document)</li> </ul>	Disorders: A Randomized Clinical Trial	
Random sequence generation	Abstract:	
	Purpose To assess effects of an inpatient multicomponent occupational rehabilitation p	rogram compared to less compre
	sickness absence in persons with musculoskeletal- or mental health disorders. Methods	Randomized clinical trial with pa
🗆 High / unclear 🛛 Info	individuals 18-60 years old on sick-leave for 2-12 months with a sick-leave diagnosis w	
<ul> <li>Allocation concealment</li> </ul>	chapters of ICPC-2, identified in a national register. The inpatient program (4 + 4 days)	
<ul> <li>Blinding of participants and personnel</li> </ul>	training and work-related problem-solving including creating a return to work plan and consisted primarily of ACT (6 sessions during 6 weeks). Both programs were group base	
<ul> <li>Blinding of outcome assessment</li> </ul>	at 6 and 12 months follow-up. Secondary outcome was time until sustainable return to	
<ul> <li>Attrition bias</li> </ul>	program (n = 92) or the outpatient program (n = 76). We found no statistically significa	
Reporting bias	absence days at 6 and 12 months follow-up. In the outpatient program 57% of the part	
Other bias	in the inpatient program 49% (log rank, p = 0.167). The hazard ratio for sustainable ret	urn to work was 0.74 (95% CI 0.48
	outpatient program. Conclusions This study provided no support that the more compre	
<ul> <li>PICO text (full text)</li> </ul>	rehabilitation program reduced sickness absence compared to the outpatient rehabilitation	ition program.
<ul> <li>Sample size</li> </ul>	Author(s) Aasdahl L ; Pape K ; Vasseljen O ; Johnsen R ; Gismervik S ; Halsteinli V ; F	leten N ; Nielsen C V; Fimland M S
<ul> <li>Punchline</li> </ul>	Investigation Converting Debal Media	
	Journal Journal of Occupational Rehabilitation	

Option 2: Not blinded to your team members

# Your assignments

- 1. Fill out all 7 domains in *Risk of bias (on full document)* 
  - a) Check the correct code (Low or High/unclear)
  - b) Click on Info and add in support for your assessment. Copy the text extracted by machine learning, if you agree, otherwise copy from the pdf, or write in your own text. Specify «high» vs «unclear» in the info box.



13

### EPPI version 4 Interface


- Version 4 in internet explorer: <u>http://eppi.ioe.ac.uk/eppireviewe</u> <u>r4/eppireviewer4.aspx</u>
- Find your assignment

Docume	ents	Search	Diagrams	Freque	ncies	Crosstabs	Reports	Meta-ana	alysis Collab	o <mark>r</mark> ate	My info	S	creer	nin
					12/15 Currer	ccount exp /2020. ht Review i our accour	s private (	Expires		C	Nev	v re	view	
Select	Revi	ew		V	ID 🏹	Last Logo	n V	New ite	ms 🛛 🗸	Own	ier	7		ŀ
Go	143	Barn me	d atferdsva	nsker, p	24570	11/30/20	20 2:56:0	0		Ley	Muller		<b>/</b> ::	
Go	146	samvær	svegring		25166	12/1/202	0 1:52:44	0		Ley	Muller		<b>/</b> 18	
Go	2019-nCov mapping		21823	10/6/202	0 1:28:35	8241		The	o Lorenc	c 🥠		]=		
Go	Barn og unges medvirkning i ba		21425	11/16/202	20 2:59:3	0	0		Sari Ormstad		<b>/</b> ::			
Go	CFS aetiology and risk factors		16713	11/13/202	20 4:55:2	E 0	0		Lillebeth Larur		<b>/</b> te	j		
Go	chemsex		22297	11/10/202	20 4:23:0	0		Eirik Amunds		en	<b>/</b> t			
Go	Covi	d19 kons	sekvenser fo	or barn	24809	12/1/202	0 11:49:5	0		Ley Muller			<b>/</b> ::	
Go	Covi	d-19 livi	ng review		21865	11/23/202	20 2:44:3	0		Ley Muller			<b>/</b> ::	
Go	Labo	or activat	ion		21359	11/12/20	20 2:36:4	E 0		Ley	Muller		18	].
My wor	rk alle	ocations:											Ţ	
Codes	to ap	ply:				Group o	f studies		Alloca	ted	Started	Re	main	ing
RobotR	leviev	ver class	ifications			Risk of	Bias			5				3

- Codeset you are interested in: RobotReviewer classifications
- Open pdf: Download

i 🗔 🕦 😋 📥 👘	Citation details	Text document Reference Search Coding record Li	inked records.	PDF Arms & timepoints	
		🗭 Previous Next 🔶 🖉 Show terms 🛛 🔒	Save and clos	e 🎇 Cancel 🛛 🚯 Find	付 Translate
▷ Creen on Title ▷ Creen on full reprint the second se	aport Title	An online alcohol and risky sex prevention progra a randomized controlled trial.	ram for colleg	je students studying abroa	d: study protocol for
► 👫 🥝 🖌 Allocation codes ► 🧎 🖨 🖌 Retrieval status		Pedersen ER ; D'Amico EJ ; LaBrie JW ; Farris C ; Klei	Item IDs	Internal: 52120907 Import	ed: 31429802
🕞 🧸 🖨 🗹 Data Extraction	for MA Month	August	Pub type	Journal, Article	•
⊳ 🤱 🥝 📝 Leys test	Year	2019	Included?	$\checkmark$	
Class of this Color Reviewer     Study type classifiers     PICO Spans (from abst     MeSH Terms     Risk of bias (on full doc     Risk of bias (on abstrac     Sample size     Punchline     PICO text (full text)     Domain added by Ley     Data extraction     Sample Size     Classifiers	Abstract ract) ument) t alone)	BACKGROUND: This study protocol describes a propos- intervention study to address problematic and dangert in foreign environments. Despite universities and colles students abroad, mast institutions offer ne empirically proposed intervention attempts to fill a major gap for each year by using empirically-based and theoretically drinking norms and promote cultural engagement abra intervention seeks to prevent risky sexual behaviors (c victimization, which are strikingly common among stu psychological effects upon return home. METHODS/DE intervention with a sample of 1200 college students st The brief, online intervention is text and video based abroad and address difficulties adjusting to life in the fe- sexual behaviors of stext and video intervention (predeparture, first month abroad, last month abroad, intervention effects on drinking behavior, drinking con examine whether the mechanisms targeted by the inte experience abroad) serve as mediators of intervention	ous drinking ai ges citing alcc -/based prever the nearly 333 -/informed risk oad. In additio (e.g., sex withd dy abroad stuu ESIGN: We will utdying abroad and contains e orms, content foreign enviror road. Participai sequences, ris sequences, ris	mong young adult college stu hold misuse as the most conc tion efforts tailored to this at )000 students completing st and protective factors to con n to preventing heavy and pr ut a condom) and experience dents and have the potential conduct a randomized contri- f form approximately 50 US u vidence-based components o to promote engagement with ment, and typs and strategies that will complete online surver- return, and 3-months post- ky sex, and sexual violence of nges in perceived norms, eng	dents studying abroad erning issue for their -risk population. The vidy abroad programs rect misperceived peer of sexual violence of assual violence of assual violence of assual violence of assual violence of sexual violence of sexual violence and sexual violence personalized normative the cultural experience to prevent risky ys at five time points victomes. We will agement in the cultural
•	Files	Title V Document V Exte	ension 🏹 Rob	ot Delete View text D	Way DDE

- Turn on live comparisons to see machine learning assessments (this breaks blinding):
- Coding record → Live comparison → Citation details → click on the specific code you want to see. The child-codes immediately subordinate will be shown, so you might have to use the arrows to expand a code.



- Take a look at the information already available.
- The code relevant to you is *Risk of bias* (on full document), while this can be helpful: *PICO text (full-text)*. But the others also have interesting info.
- NB! You won't see any coding on the left side, because the assessment isn't completed yet. Look at the bottom of the screen for RR's coding, which will be marked under your team leader's name (or someone else on the machine learning team).
- Any text extracted will be in italics.

ument details							
🗓 👔 🧟 🔔 🔲 Auto advance		Citation details	Text document	Reference Sea	rch Codi	ng record	Linke
	÷	Item 1 / 2	Previous Next	-> 🖄 Show	r terms		🔏 Sav
- 👬 🖨 🔀 Screen on Title & Abstract	•	Title	A Digital Inter	vention Addre	ssing Alc	ohol Use	Proble
- 🏖 🖨 🗾 Screen on full report			Randomized Co	ontrolled Tria	•		
- 🧸 🥝 🗾 Allocation codes		Author(s)	Tait RJ ; Paz Cas	tro R; Kirkman	JJL ; Moo	re JC ; Scl	ha 1
- 👬 🖨 📈 Retrieval status		Month	September				I
- ิ 🤤 🔀 Data Extraction for MA		Year	2019				I
🤱 🥑 📈 Leys test		Abstract	BACKGROUND:				
🧥 🖨 📈 Risk Of Bias (Cochrane)			of effective inter use. OBJECTIVE				
🔒 😑 🔀 RobotReviewer classifications			was developed b	y Hello Sunday	Morning	to support	high-ri
<ul> <li>Study type classifiers</li> </ul>			alcohol. In partie to an otherwise	self-guided pro	gram (con	trol group	). METH
- Is RCT (balanced) Info	=		trial, but as som comprised all pa				
— 🔲 Is RCT (precise) Info			was change in a but other outcor				
- Is RCT (sensitive) Info			distress (Kessler	-10), and quali	ty of life (	EUROHIS-	QOL).
- Is RCT Info			site and commer RESULTS: We re	cruited 398 pe	ple to the	intervent	ion gro
Is human study Info			were female (71				
PICO Spans (from abstract)							_
MeSH Terms	(	Live comparison					
Risk of bias (on full document)			y Muller RCT (balanced)				
Risk of bias (on abstract alone)		3.9	935029				
			RCT (precise) 935029				
b→ Sample size		3.9	935029				
→ Sample size → Punchline			RCT (sensitive)				

#### Your assignments Risk of bias (on full document) Random sequence generation Low Info 🧸 😑 📈 RobotReviewer classifications – 🔲 High / unclear Info Fill out all 7 domains in Risk of 1. bias (on full document) ▶\_ Study type classifiers Allocation concealment – 🗌 Low 🔲 Check the correct code a) ⊳ PICO Spans (from abstract) b) Click on Info and add in - 🔲 High / unclear 🛛 Info MeSH Terms support for your assessment. Blinding of participants and personr Copy from RR, if you agree, Risk of bias (on full document) Low Info otherwise copy from the pdf, Risk of bias (on abstract alone) High / unclear Info or write in your own text. Specify «high» vs «unclear» Blinding of outcome assessment Sample size in the info box. Punchline PICO text (full text)



Published by the Norwegian Institute of Public Health September 2021 P.O.B 4404 Nydalen NO-0403 Oslo Phone: + 47-21 07 70 00 The report can be downloaded as pdf at www.fhi.no/en/publ/